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Endothelial progenitor cells (EPCs) are bone marrow derived stem cells that contribute
towards neovascularisation. I have primarily used real time polymerase chain reaction
(PCR), but also flow cytometry and cell culture techniques, to investigate the effect of
vascular injury on the expression of the putative markers of EPCs (CD34, CD 133,
VEGFR-2 and VE-cadherin) and their number in peripheral blood.
Preliminary studies were performed in order to optimise the real-time PCR assay, which
was performed using the ABI 7900™ Taqman PCR system. It was shown that the
relative quantities (RQ) of messenger RNA (mRNA) for the markers of EPCs were
stable over a 24-hour period, with no significant reduction in expression when blood
samples were serially sampled under different conditions. In addition, ribosomal 18s was
found to be the best endogenous control. Furthermore, the coefficient of variation for the
real-time PCR assay was shown to be less than 10%. Finally, the RQ of EPC mRNA
was shown to vary depending on the type of source material, but was generally greater
in cord blood, mobilised peripheral blood and bone marrow compared with peripheral
blood.
In the first study I investigated the effect of percutaneous coronary intervention (PCI) on
EPCs in a group of patients with stable coronary disease. After PCI, EPC markers did
not conclusively demonstrate a rise in expression, although the number of VEGFR-2+
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cells did increase. However, the number of EPC colony forming units (CFUs) increased
significantly.
In the next study, I investigated the effect of open aortic aneurysm repair on EPCs in a
group of elective surgical patients. There were changes in the level of expression of EPC
markers, using both real-time PCR and flow cytometry, but statistical significance was
not reached. However, there were significant increases in the mean fluorescent
intensities (MFI) of VEGFR-2 and VE-cadherin expression. EPC-CFUs did not change
significantly.
The next study investigated the effect of type 1 diabetes on EPC levels. The percentage
of CD34+ cells, the RQ of VE-cadherin mRNA and the number of EPC-CFUs were
significantly reduced in the diabetic cohort compared with control groups.
Finally, the effect of chronic renal impairment and administration of human recombinant
erythropoietin (Epo) on EPC levels was investigated. The RQs of CD34, VEGFR-2 and
VE-cadherin mRNA species increased over the period analysed, but this increase did not
correspond with an increase in VEGF expression.
This thesis provides further insight into the effect of endogenous and exogenous causes





1.1. General overview and aims of thesis
An intact vascular network is a prerequisite for normal cellular function. As cells and
organs grow this network must adapt to the changing environment. In the embryo, new
blood vessels develop from primitive stem cells, which differentiate into mature
endothelial cells by a process called vasculogencsis. In adults, new blood vessels are not
only required for tissue growth, but also for revascularisation of damaged or ischaemic
tissue. This was originally thought to occur by angiogenesis, which is vascular sprouting
and intussusception, followed by myogenesis. However, recent studies have focussed on
the ability of bone marrow derived stem cells in adults to participate in new vessel
formation, both in physiological and pathological settings, by a process called postnatal
vasculogenesis.
The introduction will begin by defining a stem cell, and distinguishing between
embryonic and adult stem cells. A description of embryonic and adult vasculogenesis
will be made, followed by a phenotypic characterisation of the cell thought to be critical
in the process in the adult, the bone marrow derived endothelial progenitor cell (EPC). A
section will follow this on mobilisation and homing of EPCs to sites to
neovascularisation, including exogenous factors that can affect their release from the
bone marrow. In addition, there will be a summary of the role of EPCs in physiological
and pathological adult vascular development. Finally, there will be a discussion on the
clinical implications of EPCs for therapeutic vasculogenesis.
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The aim of this thesis is to investigate the effect vascular injury has on EPC marker
expression and EPC numbers. Peripheral blood samples, taken from human subjects,
will be analysed using primarily real-time PCR, but also flow cytometry and cell culture
techniques. The subjects will undergo elective percutaneous coronary intervention (PCI)
or aneurysm repair (as examples of exogenous vascular injury), or be patients with
diabetes or chronic renal failure (as examples of endogenous vascular injury). The
specific aims of this thesis are as follows:
1. To design novel assays for quantitation ofmRNA for the putative markers of
EPCs CD34, CD 133, VEGFR-2 and VE-cadhcrin, as well as the marker for
mature endothelial cells (vWF) and monocytes (CD 14).
2. To use these assays in combination with flow cytometric and cell culture
techniques to measure EPCs in patients undergoing PCI or elective aortic
aneurysm repair to see it vascular trauma affects these cells in the post
operative period.
3. To measure EPCs, using the above techniques, in a group of patients with
type 1 diabetes and compare the results with a control group.
4. To measure EPCs using real-time PCR in patients with chronic renal failure
commencing recombinant human erythropoietin (Epo) to determine whether
the hormone can affect mRNA levels of EPC markers.
5. To compare and contrast the different assays employed in the measurement
of EPCs.
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1.2. Stem cells and progenitors: general terms and definitions
Terminology surrounding stem cells and progenitor cells is confusing. Essentially there
are two kinds of stem cell in the body, originating from embryonic or adult tissues. A
working definition of stem cells is primitive entities that are clonal, self-renewing,
pluripotent, and have the ability to repopulate a tissue in vivo. The clonality and self-
renewing capacity of a stem cell refers to its ability to produce more identical stem cells
for the lifetime of the organism; potency refers to the ability of stem cells to produce
multiple differentiated cell types. Tissue repopulation requires a stem cell to home to a
particular site, where it must differentiate into tissue specific cells. This definition can be
readily applied to embryonic stems cells, but it is thought to be too broad for adult stem
cells. These cells have, up until recently, been thought to have a more limited potential
for differentiation, and have been termed multipotent. Furthermore, unipotent adult stem
cells, better defined as progenitor cells, have been shown to be descendents of
multipotent stem cells, with a reduced ability for self-renewal and a reduced potency.
1.3. Embryonic stem cells
Embryonic stem cells are derived from a blastocyst that is developed from an in vitro
fertilised egg. They were first established in the 1980s from murine embryos, and were
derived fro the inner cell mass of an expanded blastocyst at 3.5 days post-coitum under
strict culture conditions. Human embryonic stem cells were first isolated from in vitro
fertilised blastocysts in 1998. They were shown to have a high nuclco-cytoplasmic ratio,
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a high transcriptional activity and to express markers that were down regulated upon
differentiation. The interest surrounding embryonic stem cells arises from the potential
to use them as a therapeutic agent in tissue regeneration. The advantage of these cells is
that they are pluripotent and large numbers of them can be relatively easily obtained in
culture. However, with the ethical and legal concerns surrounding embryonic stem cells,
adult stem cells have become a focus of intense interest, because they can potentially be
expanded in culture and reintroduced into the patient without the risk of immune
rejection.
1.4. Adult stem cells
The origin of adult stem cells is less clear than for embryonic stem cells. Their existence
has been known about since the 1960s, when it was shown that blood or bone marrow
contained cells that could rescue humans and animals from bone marrow failure. Since
then other tissue-specific stem cells have been defined, including neural stem cells found
in the postnatal brain, and mesenchymal stem cells found in the bone marrow and
adipose tissue. They are thought to be responsible for regenerating damaged tissue and
maintaining tissue homeostasis. Until very recently, stem cells from adult tissue were
thought to be restricted to producing cells specific to that particular tissue. However,
recent evidence suggests that adult stem cells, rather than being multipotent in a
particular organ, are "plastic". This means that they have the capacity to differentiate
into cells of unrelated tissue in a similar way to embryonic stem cells. The traditional
paradigm on adult stem cells being lineage restricted and derived from pluripotent stem
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cells very early during development has now been put into question. There are a number
of mechanisms that could underlie plasticity seen in adult stem cells. Firstly, there is
evidence that stem cells for a given organ may exist in a distant organ. For example, it is
known that haematopoietic stem cells can also be harvested from organs such as muscle.
Second, plasticity may result from fusion between donor cells and recipient cells. For
example, it was shown that co culture of embryonic stem cells with either bone marrow
cells or neural stem cells could lead to fused cells with the functional capacity of the
former cell type, whilst maintaining expression of some genes from the latter cell types.
Furthermore, it was shown in an animal model of cirrhosis that bone marrow
transplantation resulted in hepatic regeneration by fusion between haematopoietic stem
cells and hepatocytes [1], Lastly, different stem cell populations may be more
heterogenous than previously thought. For example, it is now known that haematopoietic
stem cells contain a number of subpopulations of cells involved in various aspects of
haematopoietic repopulation. It is likely that earlier stem cells committed to a
haemangioblast or mesodermal fate are also present, with the capacity to differentiate
into non-haematopoietic cells if placed in the appropriate microenvironment. For
example, Grant et al demonstrated both endothelial and blood reconstitution following
single-cell transplant of haematopoietic stem cells (Linneg Sca-lpos c-kitpos) from mice
expressing green fluorescent protein into lethally irradiated recipients [2], One month
after the mice were haematopoietically reconstituted, a retinal injury was induced with a
laser. In every mouse that had haematopoietic reconstitution, the regenerating blood
vessels expressed green fluorescent protein.
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Adult stem cells may therefore be an alternative to embryonic stem cells as a source for
tissue regeneration. The caveat, however, is that adult stem cells appear more difficult to
grow in culture, so that obtaining clinically significant amount for therapeutic purposes
may prove problematic.
1.5. Stem and progenitor cells and the development of new blood vessels
Embryonic development and tissue regeneration in adults rely on new blood vessel
growth, termed neovascularisation. The traditional model of neovascularisation
distinguished between the process in the embryo and in the adult. Embryonic
neovascularisation was thought to occur by maturation of endothelial progenitor cells,
termed embryonic vasculogenesis. In adults neovascularisation happened solely by
sprouting of vessels from the division of differentiated endothelial cells. However, with
the knowledge that tissue specific adult stem cells exist evidence has emerged which
suggests that endothelial progenitor cells can also contribute to neovascularisation in the
adult under various physiological and pathological conditions by a process called
postnatal vasculogenesis. Blood vessel formation in the embryonic and adult will be
summarised in the following sections.
1.6. Embryonic vasculogenesis
The formation of blood vessels occurs early in the embryo, at approximately day 7.5 in
the mouse. It occurs at distinct locations in the yolk sac and within the embryo itself. In
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the yolk sac mesodermal derived cells called haemangioblasts aggregate to form blood
islands. Haemangioblasts are thought to be the common precursor of both
haematopoietic stem cells and endothelial progenitor cells (EPCs), as both cell types
develop in close association within the blood island. Cells from the outer rim develop
into EPCs, whereas inner cells develop into erythrocytes, which are the first primitive
blood cells. EPCs, also termed angioblasts, have the capacity to proliferate, migrate and
differentiate into mature endothelial cells but have not yet acquired a mature phenotype.
Within the embryo, blood vessels develop in a similar fashion from precursors within
different areas of the splanchnic and somatic mesoderm. These blood islands fuse and
grow to produce a primitive vascular plexus (vasculogenesis). Additional mechanisms
for vessel development include "bridging" and "intussusception", termed angiogenesis.
Vessel maturation then involves the endothelial-lined vessels acquiring a basement
membrane and a smooth muscle layer (large vessels) and pericyte layer (small vessels)
by a process called arteriogenesis. The acquisition of a muscular layer is determined by
blood flow and pressure, with low-pressure areas having delayed smooth muscle
differentiation. The vascular cells then acquire specialised characteristics to suit a
particular environment. For example, endothelial cells in the brain are closely associated
to produce an effective blood-brain barrier, whereas endothelial cells in endocrine
glands arc loosely associated to facilitate the passage of hormones. The molecular
mechanisms underlying these processes are not completely understood. However,
several ligand-receptor interactions have been identified that are likely to be important.
In mice the interaction between the receptor tyrosine kinase flk-1 and its high affinity
ligand vascular endothelial growth factor (VEGF) is thought to play a key role in
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haematopoietic and endothelial development. Examination of the expression of flk-1 and
VEGF in mouse embryo has demonstrated that both are present in the blood islands of
the yolk sac of day 8.5-10.5 embryos It has also been shown that mice die in utero at
days 8.5-9.5 if they are made homozygous for deficiency of the flk-1 gene. This has
been shown to be because of a defect in the development of haematopoietic and
endothelial cells. Yolk-sac blood islands are not present, organised blood vessels are not
observed at any stage, and haematopoietic progenitors are markedly reduced.
1.7. Postnatal endothelial progenitor cells
Adult bone marrow contains a sub-population of cells with properties similar to those of
embryonic angioblasts. These cells have the potential to proliferate and differentiate into
mature endothelial cells and have, therefore, been called endothelial progenitor cells
(EPCs). A landmark paper was published by Asahara et al in 1997, when EPCs were
first isolated from peripheral blood [3J. Exploiting the knowledge that there are antigens
shared by angioblasts and HSCs, they used magnetic beads coated with CD34 and Flk-1
to separate out EPCs from the mononuclear cell fraction of human peripheral blood.
These cells were then plated on fibronectin-coated surfaces. It was observed that they
quickly attached, became spindle shaped within three days, with the number of attaching
cells increasing with time. Using a fluorescent dye Dil they demonstrated that these
spindle shaped cells were derived from CD34-positive cells with the ability to form
cellular networks and tube-like structures. After 7 days in culture the attached CD34-
positive cells were seen to express endothelial cell markers by flow cytometry, and at the
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molecular level by qualitative polymerase chain reaction (PCR). Finally, it was shown in
animal models of hind limb ischaemia that these cells could contribute to postnatal
vasculogenesis in-vivo. Circulating EPCs were also identified by other groups using
similar methodologies [4-7]. In addition, it was discovered that these cells were likely to
originate from the bone marrow. Asahara et al used established two murine models of
bone marrow transplantation (BMT) [5], In each case, immunodeficient mice underwent
BMT from transgenic mice constitutively expressing p-galactosidase (lacZ) under
transcriptional regulation of an endothelial cell-specific promoter, FLK-1 or TIE-2.
Reconstitution of the transplanted bone marrow yielded Flk-l/lacZ/BMT or TIE-
2/lacZ/BMT mice, in which lacZ was restricted to bone marrow derived cells expressing
Flk-1 or TIE-2. LacZ expression was not observed in other somatic cells. Localisation of
EPCs, indicated by flk-1/LacZ or TIE-2/LacZ fusion transcripts, was identified in corpus
luteal and endometrial neovasculature after induction ovulation. In addition, injected
mouse syngeneic colon cancer cells, cutaneous wounds and induced hind limb
ischaemia, in the same mouse model, derived new vessel growth from the bone marrow
derived LacZ expressing cell population.
1.8. Characterisation of EPCs
The phenotypic characterisation of EPCs has been difficult to achieve for a number of
reasons. Firstly, it has been confounded by the presence of circulating endothelial cells
(CECs) in the peripheral circulation [8]. CECs are mature cells that are thought to
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originate from sloughing off the vessel wall following some sort of pathological insult.
Elevated numbers of CECs occur in patients with a variety of conditions associated with
vascular injury, including sickle cell anaemia [9], septic shock [10], and lupus [11]. The
features that are thought to separate CECs from EPCs are summarised in table 1,1. In
the peripheral circulation, bone marrow-derived CECs are thought to represent a small
fraction of total CECs [7]. In a series of in-vitro experiments on peripheral blood from
patients who had previously received gender-mismatched bone marrow transplants, it
was found that endothelial cell colonies that appeared in culture within nine days were
predominantly of recipient phenotypc [7]. This suggested that these cells might represent
CECs from the vascular endothelium of the recipient. In contrast, endothelial colonies
that appeared later in culture were of donor origin, suggesting that these cells derived
from bone marrow EPCs. These late outgrowth cells showed a high proliferative
capacity compared to early-outgrowth cells. Quantification of EPCs is often done using
colony-forming assays; these findings suggest that functional assays should include a
pre-plating step to eliminate the background of CECs, as has been done elsewhere and in
the series of experiments in this thesis [4, 12],
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CECs EPCs
Origin Blood vessel wall Bone marrow
Phenotype CD133 -ve CD 133 +ve
Morphology Mature cells of diameter
20-50pM
Immature cells of diameter
less than 20pM




Pathophysiology Reflective of damage Neovascularisation
CECs= circulating endothelial cells, EPCs= endothelial progenitor cells
Table 1.1. Differences between CECs and EPCs [8].
Attempts to characterise EPCs are further confounded by the fact that they are not one
type of cell but probably represent a heterogenous group of progenitor cells, each at a
different stage of maturation [13], In addition there is considerable overlap between
proteins expressed on EPCs and those expressed on cells of haematopoietic lineages,
including CD31, CD34, and vascular endothelial growth factor receptor-2 (VEGFR-2),
also known as kinase insert domain receptor (KDR) [14, 15]. Moreover, the
characteristic feature of EPCs in culture is their ability to take up acetylated low-density
lipoprotein (LDL) and to bind to specific lectins, but this feature is also shared by non-
endothelial cells [16, 17]. Despite this, however, the earliest EPCs are thought to express
CD 133, CD34, and VEGFR-2 [6, 18]. CD34+/CD133+ cells have been shown to have a
high proliferative capacity and to give rise to endothelial colonies in culture [6, 18, 19].
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CD 133 (also known as AC 133) is an early haematopoietic stem cell marker of unknown
function. It is a 120-kDa transmembrane polypeptide, and is expressed on
haematopoietic stem and progenitor cells from human bone marrow, fetal liver, and
peripheral blood [20], The number of CD 133+ EPCs as a fraction of peripheral blood
mononuclear cells is small, so this immature cell type is more likely to be present in the
bone marrow [19], In the peripheral blood EPCs appear to lose expression of CD 133 as
they mature, but continue to express VEGFR-2 and CD34. Further maturation of EPCs
results in loss of CD34 expression and gain of markers such as vascular endothelial
cadherin (VE-cadherin- CD 144) and von-Willebrand factor. However, no clear
definition exists for when an immature EPC changes into a mature endothelial cell. In
summary, it is possible that CD133+/CD34+/VEGFR-2+ cells represent a more
primitive EPC with high proliferative potential, which then gives rise to a more mature
endothelial cell with the phenotype CD133-/CD34+/VEGFR-2+/ vWF+/VE-cadherin+
with a more limited proliferative capacity. Two separate EPC populations in human
peripheral blood have been described, based on their differing proliferative potentials
[21].
It has recently been demonstrated that cells of monocytic lineage, expressing CD 14, are
a source of EPCs. Monocytes have been shown to co express endothelial lineage
markers such as VEGFR-2 and CD133 and to differentiate into adherent mature
endothelial cells and to form cord like structures in Matrigel [22, 23]. Rchman et al has
also reported that peripheral-blood endothelial-like cells are derived from
monocytes/macrophages and secrete angiogenic growth factors [24]. These cells have
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the ability to form spindle-shaped cells after several days in culture, take up LDL, and
bind a specific lectin. Furthermore, it has been shown that a specific subset of
monocytes, expressing CD 14 and VEGFR-2, have endothelial-like functional capacity,
and exhibit functional competence to improve re-endothelialisation in an animal model
of arterial injury [25],
In summary, it can be seen that at least two cell populations can qualify as EPCs, each
group containing a heterogenous sub-population of cells. A further cell group, with
endothclial-likc functional capacity, known as multipotent adult progenitor cells
(MAPCs), may also represent a further type of EPC [26], although this population is less
well defined. Furthermore, how each of these cell populations relates to the other is
uncertain.
1.9. Mobilisation, release and homing of EPCs
In order that EPCs can contribute effectively towards neovascularisation they must first
be recruited from the "stem cell niche", where stem cells are kept in an undifferentiated
and quiescent state, to the "vascular niche", where progenitor cells arc prepared for
release into the circulation. At some point they must commit to the EPC differentiation
pathway, be mobilised from the bone marrow into the circulation, and then delivered to
the appropriate site. This process is complex and involves a number of triggers,
enzymes, growth factors and cell surface receptors. An early event in mobilisation is the
activation of matrix mctalloproteinase-9 (MMP-9), which transforms membrane bound
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Kit ligand to a soluble Kit ligand (sKitL). This allows the stem cells and early progenitor
cells to detach from the local environment and to leave the bone marrow via
transendothelial migration. In MMP-9 -/- mice levels of sKitL are low resulting in
impaired progenitor cell motility, while administration of sKitL corrects this [27]. The
bone marrow is also the place where the haemangioblast will commit to either the HSC
or EPC pathways. How this occurs is largely not understood. However, it is likely that
the local cytokine environment plays a role. Certain triggers, such as tissue ischaemia,
are known to increase the levels of endogenous vascular endothelial growth factor
(VEGF), mainly due to the effects of hypoxia-inducible factor-1 (HIF-1) on VEGF
transcription [28-30]. VEGF binds to VEGFR-2, which is expressed on the
haemangioblast. In addition, VEGF has been shown to activate MMP-9 [27], Exogenous
administration of VEGF has been shown to mobilise bone marrow derived EPCs in
animal models [31]. The mobilisation is rapid; EPC levels in the peripheral blood rise
within 24 hours after VEGF administration. Furthermore, studies in humans using
plasmids containing the gene for VEGF show augmentation of circulating EPCs [32]. In
patients with vascular trauma due to severe bum injury or coronary artery bypass
grafting, EPC numbers rise by about 50 times at 12 hours post-injury, and return to
baseline by 48-72 hours [33]. Similarly, in patients with acute myocardial infarction,
levels of CD34+ cells increase one week after MI [34], The kinetics of EPC levels seen
in these patient groups closely mirrors the levels of VEGF detected in the peripheral
circulation. Stromal cell derived factor-1 (SDF-1) is a member of the chemokine CXC
subfamily and binds to CXCR4 positive stem cells. SDF-1/CXCR4 interaction has been
shown to be important in stem cell mobilisation in vivo [35], Other factors may also play
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a role in EPC mobilization, including angiopoictins, endogenous erythropoietin (Epo)
and endothelial nitric oxide synthase (eNOS) [35-40], The intracellular pathways by
which these factors mobilise EPCs have not been fully elucidated. However, it has been
demonstrated that VEGF, Epo and eNOS signal through Akt, which is a tyrosine kinase
belonging to the family of serine/threonine protein kinases [41]. Once mobilised and
released into the peripheral circulation EPCs must home to areas of neovascularisation.
This involves a multistep process beginning with (a) arrest of the EPCs at areas of
neovasculogenesis; (b) adhesion to the endothelial cells lining blood vessels; (c) and
transmigration across this surface into the interstitial space; (d) formation of cellular
clusters; (e) formation of cellular networks; and (f) incorporation into the
microvasculature [42], Using a tumour model and mouse embryonic progenitor cells
(eEPCs) Vajkoczy et al showed that initial cell arrest of eEPC homing was mediated by
E- and P-selectin and P-selectin glycoprotein ligand 1 [42, 43], In addition, it has been
demonstrated that cultured EPCs express L-selectin, and that this adhesion receptor can
interact with its ligand on endothelial cells to promote homing of the EPCs [44], This
mechanism of homing is similar to that of leukocytes with microvascular endothelium,
where intcgrins are known to be important [45, 46]. In particular |32-integrins, found on
haematopoietic cells, and a4[31-integrins, on endothelial cells, are important in cell-cell
interactions. P2 integrins have been shown to be important in adhesion and
transmigration of haematopoietic stem/progenitor cells [47, 48]. Chavakis et al have also
shown that ex vivo expanded and murine Sca-1+/Lin- progenitor cells express P2-
integrins, which mediate the adhesion of EPCs to endothelial cell monolayers and
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transendothelial migration in vitro [49]. They have also shown that in a mouse model of
hind limb ischaemia, progenitor cells from p2-integrin-dcficient mice are less capable of
homing to sites of ischaemia and promoting ncovascularisation. Attraction of the
circulating EPCs to the site of neoangiogenesis is mediate by chemokines. In particular
SDF-1, which is known to be important in homing of stem cells to bone marrow, has
been shown to stimulate recruitment of progenitor cells to sites of tissue ischaemia [50-
52], In addition, VEGF has also been shown to be important as a chemoattractant for
progenitor cells, with increased levels during an ischaemic episode [34], Less is known,
however, about EPC migration and tissue invasion. Recently the protease cathepsin-L
has been found in EPCs, and has been shown to be important in EPC invasion and
matrix degradation in vitro [53]. In addition, this group also showed that mice made
deficient in cathepsin-L had impaired functional recovery following hindlimb ischaemia,
supporting the idea that this protease has an important in-vivo role. The final step is the
differentiation of EPCs to mature endothelial cells, with integration of these cells into
vessels. Although this is not fully understood, it is thought that VEGF plays a crucial
role. This has been demonstrated at the embryonic stage, as well as in ex-vivo culture
systems[54, 55],
1.10. Exogenous factors affecting the recruitment of EPCs to the periphery
The level of circulating EPCs has been shown to vary secondary to various
physiological, pathological and pharmacological factors (table 1.2). For example, age
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and sex hormones are important determinants that need to be taken into account if EPC
numbers and function are being compared between groups in a study. It has been shown
in experimental models that revascularization is impaired in senescent animals. In
addition, older human subjects have lower numbers and impaired mobilization of EPCs
[56], Oestrogen is thought to mediate re-endothelialisation after arterial injury by its
effect on EPC mobilisation. Re-endothelialisation after carotid injury occurred faster in
ovariectomised mice treated with 17|3-oestradiol than in controls [57, 58], The
oestrogen-treated animals had increased levels of circulating EPCs and a significant
increase in bone marrow-derived cells participating in endothelial repair at the site of
injury. Of note is the observation that oestrogen did not increase EPC levels or effect re-
endothelialisation in mice deficient in endothelial nitric oxide synthase (eNOS), a
finding consistent with observations that eNOS expressed in bone marrow plays an
important role in the regulation of EPC release [57, 59], EPC numbers have also been
shown to increase in patients following acute myocardial infarction [34], The number of
CD34+ mononuclear cells increased by day 7 compared to control subjects, who had no
evidence of myocardial ischaemia. Furthermore, patients with vascular trauma from
coronary bypass grafting or burn injury had a transient rise in EPC numbers [33],
Congestive cardiac failure can also affect the number of circulating EPCs [60].
Interestingly there appears to be a biphasic pattern, with elevation in the early (class I
and II) and reduction in the advanced (class III and IV) stages. Patients with diffuse in-
stent restenosis had lower numbers of EPCs, which had an impaired adhesive capacity
in-vitro [61 J. In patients with stable coronary artery disease it has been shown that the
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number and proliferative capacity of EPCs are reduced [62, 63]. In addition, EPC
numbers are reduced in patients with risk factors for coronary artery disease, such as
genetic predisposition or smoking [64], Hill et al showed that in patients with risk
factors for coronary artery disease the ability of EPCs to form colony forming units
(CFUs) was inversely related to the Framingham risk score [12]. In addition, they found
a direct correlation between numbers of EPCs and their function, with cells from high-
risk patients showing increased senescence compared to lower risk patients. They
concluded that EPC number and function could be used as an independent risk factor for
coronary artery disease. Drug therapy can also affect EPC numbers. The best-
characterised group of drugs in this respect are the HMG-CoA (3-hydroxy-3-
methylglutaryl-CoA) reductase inhibitors ("statins"). This class of drugs may have a
beneficial effect on vascular health independent of their ability to lower blood
cholesterol [65], Simvastatin has been shown to increase EPC CFUs from cells taken
from treated animals, and to have migratory effect on mononuclear cells in an in vitro
chemotaxis assay [66], In addition, HMG-CoA reductase inhibitors have been shown to
mobilize EPCs which can help to repair damaged coronary arteries [67], This
mechanism of action is via activation of the PI3-kinase/Akt pathway in EPCs, and
requires the presence of endothelial nitric oxide [68, 69]. Cytokines have been used to
mobilize EPCs and increase their number in the circulation. Granulocyte colony
stimulating factor (G-CSF) administered to humans has been shown to increase the
number of circulating EPCs to 5- to 10-fold [18]. In addition, G-CSF has been used to
increase the number of EPCs in patients with coronary artery disease, where baseline
levels arc lower than in control subjects [70], In animal studies G-CSF has mobilized
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EPCs sufficiently to accelerate vascular repair following injury and to increase
endothelialisation of prosthetic vessels [71, 72], The use of G-CSF for therapeutic
neovascularisation of ischaemic tissue and for ex-vivo expansion of EPCs in patients has
been performed, and will be discussed later [73]. Increased numbers of EPCs can also be
seen in mice and rabbits treated with granulocyte macrophage colony stimulating factor
(GM-CSF), and enhanced neovascularisation with bone marrow-derived cells is seen in
mice treated with GM-CSF in a corneal neovascularisation model [74]
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Condition or factor Changes in number/function of EPCs Reference
Physiological
Age Decreased number [56]
Gender (eg oestrogens) Increased number [58]
Physical training Increased number [75, 76]
Pathological
Coronary artery disease Decreased number and function [62-64]
Smoking Decreased number [64, 77]
Family history of coronary artery disease Decreased number [64]
Hypertension Decreased function [64, 78]
Cumulative cardiovascular risk factor score Decreased number [12]
Myocardial infarction Increased number [34]
Vascular injury Increased number [33]
Congestive cardiac failure (class I-II) Increased number [60]
Congestive cardiac failure (class III-IV) Decreased number [60]
In-stcnt restenosis Decreased number and function [61]
Diabetes Decreased number and function |64, 79,80]
Uraemia Reduced number [81,82]
Hypercholesterolaemia Decreased number and function [83]
Systemic inflammatory conditions Increased numbers |84-86]
Surgery Increased number [87]
Drugs and cytokines
HMG-CoA reductase inhibitors Increased number and function [66-69, 88,
89]
G-CSF Increased number [70,71]
Erythropoietin Increased number [40, 90]
Table 1.2. Exogenous factors affecting the recruitment of EPCs to the periphery.
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1.11. EPCs and tumour angiogenesis
There is a growing amount of evidence from animal models indicating that bone EPCs
contribute to tumour neovascularisation, and that in the peripheral blood of patients with
cancer there is an increased number of circulating CECs that may also participate in
vessel formation [91-94], How EPCs contribute to tumour expansion is uncertain, but it
could be by directly incorporating into the vascular endothelium of the tumour, or by
secretion of proangiogenic growth factors in perivascular sites within the tumour. In one
study, murine colon cells were subcutaneously injected into mice that underwent bone
marrow transplantation from transgenic mice constitutively expressing |3-galactosidase
gene regulated by an endothelial cell-specific promoter [5], Three weeks after tumour
implantation, histological examination of the tumour revealed multiple LacZ-positive
cells in the tumour stroma and in the endothelial layer of tumour blood vessels. Factors
known to mobilise EPCs from the bone marrow have also been shown to alter tumour
growth, probably by regulating tumour angiogenesis. G-CSF has been shown to increase
tumour growth in mice, and this has been attributed to increased tumour
neovascularisation with increased bone marrow-derived cells being observed within
tumour vasculature [95]. A further study has used a transgenic mouse model of multistep
carcinogenesis to look at incorporation of bone marrow-derived cells into the
ncovasculature of a tumour [96], Integration of bone marrow cells into the tumour
vasculature was demonstrated, which correlated with VEGF release by the tumour and
mobilisation of circulating EPCs in the periphery. Further evidence supporting the
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existence of a bone marrow-derived component of tumour neovascularisation has come
from studies of mice with mutations in the Id family of proteins. There are four members
(Id 1 -Id4) that interact with basic-loop-helix transcription factors to regulate
differentiation and cell cycle progression [97], Two members of the Id family, Idl and
Id3, are co expressed in embryonic vasculature. Knocking out both copies of Idl and Id3
is incompatible with life. Mice lacking Id3 and with one functional copy of Id I (Id+/-
Id3-/-) do not die in development but show defects in postnatal angiogenic sprouting and
suppressed tumour growth [92], Overall survival of these mice is increased after tumour
cell implantation compared to wild-type mice. However, tumours grow normally in Id
mutant mice transplanted with bone marrow from wild-type mice. Through genetic
marking, it was determined that 90% of tumour blood vessels of these animals originate
from the bone marrow. Conversely, wild-type mice that receive bone marrow transplants
from Idl+/-Id3-/- animals abnormalities in their ability to support tumour angiogenesis
and growth. Furthermore, Idl+/-Id3-/- mice have lower numbers of circulating EPCs
than wild type mice at baseline, and a decreased EPC response to VEGF or to tumour
implantation. These observations strongly suggest that the failure of bone marrow-
derived EPCs to incorporate into tumour vasculature explains the defect in tumour
angiogenesis seen in Idl+/+ld3-/- mice, and highlights the importance of bone marrow-
derived EPCs in supporting tumour angiogenesis. The importance of Id genes in tumour
angiogenesis has also been observed in PTEN+/- mice, which exhibit spontaneous
lymphomas, uterine carcinomas, prostate intraepithelial neoplasias and
pheochromocytomas [98]. When PTEN+/- mice were crossed with Id mutants tumour
angiogenesis and growth was suppressed. In addition, when PTEN+/-Id wild-type mice
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received bone marrow transplants from LacZ+ bone marrow, 17% of tumour vessels in
uterine tumours were LacZ+. These findings suggest that EPCs make a significant
contribution to tumour neovascularisation in spontaneously arising tumours. However,
contrary to the findings ofmost studies, some reports have found that the contribution of
bone marrow-derived EPCs to tumour vascular growth was minimal [99, 100], This lack
of consensus may be explained in part by different experimental settings, such as type of
cells used to transplant animals (whole bone marrow vs. purified primitive stem cells),
tumour type, and the time frame of the experiment and method of endothelial cell
identification.
1.12. EPCs and endothelial maintenance and regeneration
Damage to the endothelium plays an important part in the development of
atherosclerotic disease. Whereas, previously the endothelium was thought of as merely a
static barrier, the current opinion is that it is a dynamic organ. Furthermore, there is a
continual damage and repair process occurring, with the balance ultimately determining
the rate of atherosclerotic disease progression. EPCs are now thought to be integral in
repairing the damaged endothelium. This potential has been demonstrated in animal
models of mechanical vascular injury [4, 67, 101]. Insights on the role of EPCs in
atherosclerosis have also been obtained from experiments in ApoE-/- mice. Rauscher et
al investigated the effect of aging on EPCs in ApoE deficient mice [102], They found
that injection of bone marrow-derived cells in the mice maintained on high-fat diets
significantly reduced the atherosclerotic burden in these animals compared to controls.
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In addition, they found that old ApoE deficient mouse bone marrow injections did not
prevent atherosclerosis in the high fat diet fed ApoE-/- mice, but young bone marrow
infusions did. Analysis of the young and old bone marrows found reduced vascular
progenitor cells markers in the old marrow with no change in the number of
haematopoietic stem cell markers or generalised murine stem cell markers. This result
suggests an important role for EPCs in endothelial repair and attenuation of
atherosclerosis. It also suggests that older animals may be more prone to atherosclerosis
due to impaired EPC function. Studies in patients with atherosclerosis or with risk
factors for atherosclerosis also suggest an important role for EPCs in maintaining
vascular integrity. Studies have shown that the presence of disease or risk factors for
disease correlate with decreased numbers and diminished functional capacity of
circulating EPCs [12, 62, 64, 79, 81]. Hill et al described a reduction in EPC colony
forming units in healthy individuals with risk factors for cardiovascular disease [12].
Furthermore, they showed that circulating levels of EPCs were better predictors of
preserved vascular reactivity than the presence or absence of traditional cardiovascular
risk factors. In addition, EPCs from patients with multiple cardiovascular risk factors
had higher rates of in vitro senescence than those with few risk factors. Taken together
with the data from the ApoE-/- model, one explanation for this could be that subjects
exposed to continuous endothelial damage exhaust a presumably limited supply of
functional bone marrow-derived EPCs, further increasing their predisposition to
atherosclerosis owing to lower numbers of poorly functioning EPCs that remain in the
bone marrow. It would also explain why an inverse correlation between age and number
of EPCs has been observed, where an increase in cardiovascular mortality is associated
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with normal aging. However, this explanation is undermined by the fact that patients
with coronary artery disease can have their EPCs mobilised by G-CSF, statins or by
exercise with or without ischaemia [75, 103-105], An alternative explanation, therefore,
is that the pathway controlling EPC release is down regulated by exposure to risk factors
rather than EPCs themselves being consumed. Further evidence for the protective effect
that EPCs have on vascular integrity comes from a mouse vein graft model of
atherosclerosis [106], Using this model in transgenic mice carrying LacZ genes driven
by an endothelial TIE2 promoter, and hence expressing P-galactosidase only in
endothelial cells, it was shown that endothelial cells of vein grafts were regenerated
from circulating progenitor cells and not from migration of neighbouring mature
endothelial cells [107], EPCs have also been shown to play a role in arterial injury in a
murine aortic allograft model, where recipient-derived endothelial cells rcpopulated the
graft, although only a small percentage of the cells seemed to come from the bone
marrow [108, 109], Finally, EPCs may be important in maintaining intracoronary stent
patency following coronary angioplasty [61]. In summary, EPCs may be important in
endothelial repair in a variety of contexts, and levels of circulating EPCs may correlate
with the overall vitality of the vascular repair mechanism.
1.13. Clinical applications of EPC mediated neovascularisation
The potential of EPCs to contribute towards neovascularisation in vivo was initially
investigated using animal models of tissue ischaemia. One animal model that has been
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extensively used is the hind limb ischaemia model. Essentially, in a mouse all flow
through the femoral artery to the limb is diverted by ligating and then transecting the
artery below the ligature. This significantly reduces, but does not stop, blood to the limb.
Another animal model used is the myocardial ischaemia model. Myocardial ischacmia is
induced in rodents by ligating the left anterior descending coronary artery. EPCs can be
obtained from the mononuclear cells fraction of healthy human adult whole blood, for
example, and cultured in appropriate medium before being harvested. The ex-vivo
expanded EPCs are normally labelled with a fluorescent dye (carbocyanine 1,1'-
dioctadecyl-1 to 3,3,3',3'-tetramethylindocarbocyanine percholate, also know as Dil
dye) prior to being injected into the animal model. Certain parameters can then be
measured, for example change in blood flow through the ischaemic tissue or serial
echocardiography, to see if the EPCs have had a beneficial effect on tissue
neovascularisation and function. New blood vessel growth can also be looked at using
immunohistochemistry to determine the fate of the labelled EPCs. When Asahara et al
isolated endothelial cells they also investigated their in vivo ability to form new blood
vessels using the hind limb ischaemia model [3], They injected human Dil labelled
CD34+ cells into mice two days after creating unilateral hind limb ischaemia.
Histological examination of the ischaemic limb 1 to 6 weeks later showed a number of
Dil-labelled cells in the limb, with nearly all labelled cells integrating into capillary
walls. By 6 weeks Dil-labelled cells were arranged into capillaries among preserved
muscle structures. The ability of these cells to have an impact on tissue viability was
demonstrated by Kalka et al [54], They cultured human peripheral blood mononuclear
cells. Differentiating EPCs were identified after 7 days culture by using two fluorescent
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markers (FITC-labelled Ulex europaeus agglutinin and Dil-labelled acetylated low
density lipoprotein). A hind limb ischaemia model was used, and EPCs were injected
into the animal 1 day after femoral ligation. Using serial laser Doppler perfusion
imaging it was observed that there was improvement in blood flow recovery in the
ischaemic limb. More importantly, limb necrosis and auto amputation were reduced by
50% in comparison with control animals, which either received differentiated ECs or
culture media alone. Similar work has been done by Kawamoto using a rat myocardial
ischaemia model [110]. Dil labelled EPCs were injected intravenously 3 hours after
induction of myocardial ischacmia. Seven days later, fluorescence-conjugated
Bandeiraea simplicifolia lectin I (which is a murine-specific EC marker) was given
intravenously, and the rats killed immediately. Microscopy showed that the transplanted
ECs gathered in the ischaemic area and incorporated into foci of neovascularisation.
Furthermore, compared to rats injected with culture media only, when heart function
was assessed by echocardiography rats that received EPCs developed ventricular
dimensions that were significantly smaller and fractional shortening that was
significantly greater. In addition, regional wall motion was significantly greater in the
EPC group. The overall interpretation of these animal studies and others has been
complicated, however, by the fact that many use unfractionatcd bone marrow as the
therapeutic agent, whereas others use different types of purified cell populations that
represent cells with varying degrees of EPC-like properties.
With this background in mind research has now turned towards the therapeutic use of
EPCs in humans with ischaemic disease (table 1.3). Most of these small studies have
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looked at patients with acute myocardial infarction or chronic myocardial ischaemia
with no option for revascularisation by traditional means. Although many report positive
findings with few adverse effects, the follow-up period for most trials has been less than
one year, and few trials have been done in a randomised, controlled fashion. Many of
these studies report increases in myocardial perfusion, consistent with animal data that
suggest that angiogenesis or vasculogenesis may be augmented after cell transplantation.
Moreover, cells injected are generally heterologous, therefore the mechanism of benefit
is unclear, and the relative contribution of EPCs to the observed benefit is difficult to
establish [111]. Another problem with using EPCs in the clinical setting is that they are
found in low numbers in the peripheral blood. There are a number of ways that this can
be overcome, including: (i) the local infusion of autologous bone marrow cell
suspensions without pre-selection, (ii) the mobilisation of autologous EPCs in vivo, or
(iii) the ex vivo transfection with different genes. Infusion of bone marrow cells was
performed on humans with chronic limb ischaemia [112]. Twenty-two patients with
bilateral leg ischaemia were recruited. For each patient one leg was randomly injected
with autologous bone marrow mononuclear cells (BMMCs) and the other leg was
randomly injected with peripheral blood mononuclear cells (PBMCs) as a control.
Patients were assessed for changes in ankle-brachial index (ABI), transcutaneous oxygen
pressure (Tc02), rest pain and pain-free walking time. At 4 weeks ABI was significantly
improved in legs injected with BMMCs compared with those injected with PBMCs.
Similar improvements were seen for TcCE, rest pain and pain-free walking and these
effects were sustained at 24 weeks. Further studies have shown the beneficial effect of
BMMCs or ex vivo expanded autologous EPCs for repair of ischacmic and infarcted
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myocardium in humans. Of particular attention is the MAGIC trial in which 27 patients
with myocardial infarction and requiring coronary stenting were randomized to three
groups; (i) infusion of mobilized PBMCs using G-CSF, (ii) administration of G-CSF
alone and (iii) control group [113]. Exercise capacity myocardial perfusion and systolic
function were significantly improved in the cell infusion group at 6 months follow up.
Importantly, however, an unexpectedly high rate of in-stent restenosis was noted in
patients who received G-CSF, so the trial was stopped prematurely. Similarly suggested
a potential increase in adverse effects in patients with chronic myocardial ischaemia
treated with G-CSF [114]. This has, therefore, raised concerns about the safety of such
procedures, and prompted a search for other agents that can promote EPC mobilisation
without the risk of augmenting a generalised inflammatory response. Another potential
complication of cell therapy for subjects with myocardial ischaemia is intracoronary
administration of the cells. A study in which mesenchymal stromal cells were injected
into the coronary circulation of healthy dogs precipitated ECG changes compatible with
acute myocardial ischaemia 7 days later, with raised cardiac troponin I and histological
evidence ofmyocardial fibrosis [115].
In the treatment of cancer, inhibition of EPC mobilisation from the bone marrow has
tremendous therapeutic potential, as evidenced by the ability of tumours to grow in
animals that lack functional EPCs [92, 116]. Preliminary work in animal models
suggests that agents that inhibit EPC mobilisation may be effective cancer therapeutics
[117]. Further work will be required, however, before this strategy can be applied to
human neoplasms.
42
Reference Controls Pathology Patient Cells Mode of Result Adverse Follow-up
numbers used injection effects period
[118] None Chronic 5 BMMCs Intramyocardial Improved None 1 year





[112] Each Bilateral 22 BMMCs i.m. Improved None 4 weeks
patient limb (n=22, (gastrocnemius) ABI, Tc02, and 24
acting as ischaemia injected rest pain and weeks
own into one pain free






|119] 10 Acute MI 10 BMMCs Intracoronary Fewer None 3 months
patients dysfunctional
refusing myocardial
cell segments at 3
therapy months
[120] Matched Acute MI 20 BMMCs Intracoronary Improved EF Stent 4 months
reference (n=11) compared to restenosis





Reference Controls Pathology Patient Cells Mode of Result Adverse Follow-up
numbers used injection effects period
|121] None Chronic 6 CD 133+ Intramyocardial Improved EF, Pericardial 9-16
MI BMMCs during CABG perfusion to effusion in months
peri-infarct 2/6
zone patients





[111] 7 patients- Chronic 14 BMMCs Percutaneous Reduction in None 2-4




|113] 7 patients Acute MI 20 Mobilised Intracoronary Exercise Increased 6 months
having PBMCs capacity, restenosis
coronary (n= 10) myocardial in 5/7
stcnting G-CSF perfusion and patients in
only alone systolic cell
(n=10) function infusion






Reference Controls Pathology Patient Cells used Mode of Result Adverse Follow-
numbers injection effects up
period
[123] 30 Acute MI 30 BMMCs Intracoronary Increased None 6





|124] None Chronic 14 BMMCs Injection into Improved None 10






[125] None Ischaemic 6 PBMCs Intramyocardial Improved Death 4-10
cardiomyopathy after G-CSF and EF, from months
mobilisation intracoronary improved sepsis
injection while myocardial (1/6),
performing perfusion AF with
CABG RVR
(1/6)
Table 1.3. Current trials involving the use of EPCs as a therapeutic intervention in






RNA isolation from whole human blood was performed using the QIAamp® RNA
Blood Mini Kit (Qiagen, Crawley, West Sussex, UK), following the protocol supplied
with the kit. The main reasons for using a kit method as opposed to the acid-guanidium-
thiocyanate method or CsCl step-gradient ultracentrifugation was because of ease of use
and the ability to process multiple blood samples simultaneously in a shorter time
period. The kit contained:
• Spin columns- contained in 2ml collection tubes. For separating out total RNA using
a silica-gel-based membrane.
• Shredder columns- contained in 2ml collection tubes. For homogenization of cell
lysates.
• EL buffer- a hypotonic buffer that facilitates selective lysis of erythrocytes.
• RLT buffer- for cell disruption. P-mercaptoethanol was added prior to use (lOpl to
lml of buffer).
• RW l buffer- wash buffer.
• RPE buffer- wash buffer. 4 volumes of 100% ethanol was added prior to use to
obtain a working solution.
• RNase free water- for elution of total RNA from silica-gel-based membrane.
• 2ml collection tubes.
• 1.5ml collection tubes.
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Method
1. 1ml of EDTA anticoagulated whole blood was mixed with 5ml of EL buffer in a
15ml centrifuge tube.
2. The mixture was then incubated for 15 minutes on ice, and vortexed twice during
incubation. Translucency of the suspension was looked for, indicating that lysis of
erythrocytes had occurred.
3. The mixture was centrifuged at 400xg for 10 minutes at 4°C, and the supernatant
containing lysed erythrocytes was completely removed and discarded.
4. 2ml ofEL buffer was then added to the remaining cell pellet, which was resuspended
by a brief vortex.
5. The mixture was then centrifuged again at 400xg for 10 minutes at 4°C, and the
supernatant was completely removed and discarded to prevent interference with cell
disruption and RNA binding to the spin column.
6. 600pl of RLT buffer was then added to the pelleted leukocytes, and vortexed to mix.
It was ensured that no cell clumps could be seen prior to commencing the
homogenization step.
7. The lysate was then transferred into a shredder column and centrifuged in a micro
centrifuge for 2 minutes at 13,000 rpm to homogenize. The column was then
discarded and the homogenized lysate saved.
8. 600pi of 70% ethanol was then added to the lysate, in order to optimise binding
conditions for the RNA, and mixed by pipetting.
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9. The sample, including any precipitate that may have formed, was then transferred to
a spin column and centrifuged in a micro centrifuge for 15 seconds at 10,000rpm. As
the maximum loading volume of the column is 700pl this step was performed on
successive aliquots of the same sample through the same column. Following
centrifugation the flow-through and collection tube were discarded and the column
saved.
10. The spin column was then transferred to a new 2ml collection tube, and 700pl of
RW1 buffer was applied to the column, which was centrifuged at 10,000rpm for 15
seconds to wash. The flow-through and collection tube were then discarded and the
column saved
11. The spin column was transferred to a new 2ml collection tube, and 500pl of RPE
buffer was applied to the column, which was centrifuged at 10,000rpm for 15
seconds. The flow-through and collection tube were then discarded and the column
saved.
12. The spin column was transferred to a new 2ml collection tube, and a further 500pl of
RPE buffer was added to the column, which was centrifuged at 13,000rpm for 3
minutes.
13. To eliminate any chance of RPE buffer carryover, the spin column was transferred to
a new 2ml collection tube and centrifuged at 13,000rpm for I minute.
14. The spin column was then transferred to a 1.5ml collection tube, and 50pl of RNase-
free water was pipetted directly onto the membrane. The column was spun in a micro
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centrifuge at 10,000rpm for 1 minute to elute the RNA. Step 14 was repeated to
obtain a total volume of 1 OOpl containing eluted RNA.
15. To determine the concentration of RNA present 4pl of the eluted RNA solution was
added to 996pl of distilled water and the optical density was read using UV light at
wavelengths of 260nm and 280nm*.
* The 260nm reading in Absorbance units (A) (calibrated to 0.0A for distilled water)
multiplied by 104 gives an approximate concentration of RNA in nanograms per micro
litre. For example, 0.018A at 260nm = 180ng/pl. This also allows estimation of purity of
the sample from protein contamination. A ratio for the optical density at 260nm: 280nm
of around 2:1 suggests a pure sample with little contamination.
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2.2. Reverse transcription to complementary DNA (cDNA)
Introduction
In order to be able to quantify mRNA in the real-time PCR it first has to be converted
into cDNA. This depends on the enzyme reverse transcriptase (RT) to create a double
stranded DNA copy from the single stranded RNA strand.
Method
All reagents were obtained from Promega, Southampton, UK.
1. lpl (0.5pg/pl) of random hexamers was added to lOpl of RNA (lpg of RNA
made up to lOpl with DEPC distilled water) in a sterile RNase-free micro
centrifuge tube.
2. The tube was heated to 70°C for 5 minutes to melt secondary structure within the
template, then cooled on immediately on ice for 5 minutes to prevent secondary
structure from reforming.
3. On ice the following components were added to the annealed random
hexamers/template: lpl (200units) of M-MLV RT, 0.625pl (40units/pl) of
RNase inhibitor, 5pl of dNTP mix (containing dATP, dCTP, dGTP and dTTP,
each at a concentration of lOnM in water) and 5 pi of 5X RT reaction buffer
(diluted 1:5, containing 50mM Tris-HCL-pH 8.3 @ 25°C, 75mM KCL, 3mM
MgCf and lOmM DTT).
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4. The tube was then incubated for 10 minutes at 25°C followed by a 60 minute
incubation at 37°C
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2.3. Polymerase chain reaction (PCR)
Introduction
Reverse transcriptase PCR (RT-PCR) is used to amplify RNA. The principle underlying
PCR is well known. Traditionally PCR has relied on the detection of product at the end
of the reaction by using agarose gels (end-point PCR) (figure 3.5). Now, with the
advancement in PCR technology, it is possible to detect product while the reaction is
occurring (real-time PCR). This process is summarised in figure 2.1. Measuring the
kinetics of the reaction in the exponential phase of PCR provides distinct advantages
over end-point PCR. The main one is the ability to accurately quantitate an amplicon.
Quantitation of mRNA relies on the use of TaqMan® probes. These probes are
oligonucleotides, which are designed to anneal to a specific sequence of template
between the forward and reverse primers. The probe sits in the path of the DNA
polymerase as it starts to copy cDNA. When the enzyme reaches the annealed probe the
5' exonuclease activity of the enzyme cleaves the probe. The TaqMan® probe is
designed with a high-energy dye termed a reporter at the 5' end, and a low-energy
molecule termed a quencher at the 3' end. When this probe is intact and excited by a
light source, the reporter dye's emission is suppressed by the quencher dye as a result of
the close proximity of the dyes. When the probe is cleaved by the 5' nuclease activity of
the enzyme, the distance between the reporter and the quencher increases causing the
transfer of energy to stop. The fluorescent emissions of the reporter increase and the
quencher decrease. The increase in reporter signal is captured by the sequence detection
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instrument and displayed by the software in the form of an amplification plot. The
amount of reporter signal increase is proportional to the amount of product being
produced for a given sample. The amplification plot displays the threshold line and the
cycle threshold (Ct), both of which are important for the quantitation of RNA. The
threshold line is the level of detection at which a reaction reaches a fluorescent intensity
above background, and is set in the exponential phase of the amplification for the most
accurate reading. The Ct is the cycle at which the sample reaches this level.
There are two main ways of quantifying RNA by real-time PCR. The first is by absolute
quantitation. This is unnecessary in most cases, however, and requires standards whose
concentrations are known absolutely. The second approach is by relative quantitation.
This method compares target signals in different samples to a reference sample. To
correct for differences in the amount of cDNA added to a reaction or to compensate for
different levels of PCR inhibition each target signal is normalised to an endogenous
control. This is a "housekeeping gene" the amount of which will not vary greatly
between samples. The endogenous control used here was ribosomal 18s RNA (see
section 3.2). The relative difference between samples is then calculated. If the
efficiencies of the target and the endogenous control reactions are equivalent then a
standard curve is not needed and the comparative Ct method can be used (see section
3.3). Real time quantitative PCR was performed using the ABI Prism® 7900 system




All primer and probe sets were ordered through Applied Biosystems Assays-on-
Demand™ service. Each Assay-on-Demand™ gene expression product consisted of a
20X mix of unlabelled PCR primers and TaqMan® MGB probe (FAM™ dye-labelled).
These assays have been specifically designed for the detection and quantitation of
specific human genetic sequences in RNA samples converted to cDNA. Each assay has
been optimized and validated to ensure that there are comparable efficiencies between
target and endogenous control reactions if performed in separate wells (singlcplex
assay). Although the exact primer and probe sequences are not supplied by the company,
each set of assays goes through an 8 point manufacturing process, as shown in table 2.1.
The conditions which must be adhered to for primer/probe design for use of the ABI
7900 quantitative PCR system are shown in table 2.2. The gene expression products
purchased were for quantitation of mRNA of CD34, VEGFR-2, CD133, CD14, VE-
cadherin, vWF and 18s. In addition, each gene expression product has been optimised to
work with pre-developcd TaqMan® Universal PCR master mix.
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Step 1 Benefit
• Obtain transcript sequence, mask Assay designs avoid regions of ambiguity,
repeats, and map to genome resulting in assays with high fidelity
• Mask sequence discrepancies
between public and private
databases
• BLAST transcript sequence versus
Celera SNP database and mask
SNP locations
Step 2 Benefit
• Choose assay target position where Designing assay over an exon-exon
possible over an exon-exon junction helps to prevent the detection of
junction contaminating genomic DNA
Step 3 Benefit
• Apply optimal design parameters High quality 5' nuclease assays
for good 5' nuclease assay
Step 4 Benefit
• BLAST probe and primer designs Chosen assays detect only transcript(s)




• BLAST probe and primer designs
versus genome databases
Benefit
Avoid assays that detect pseudo-genes or
genomic DNA
Step 6
• Apply penalty to assays that span a
small intron
Benefit
Gene-specific assays will not amplify
contaminating genomic DNA
Step 7
• Synthesise and QC probes and
primers: mass spec and yield
Benefit
Proper probe and primers are
manufactured at the correct concentrations
Step 8
• Formulate probe and primers into




Table 2.1. The TaqMan® gene expression assay design schematic. Taken from
Applied Biosystems website (www.appliedbiosvstems.com).
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Primer
• Tm (melting temperature) 58-60°C
• 20-80% of nucleotides GC
• Length 9-40 bases
• <2°C difference in Tm between the two primers
• Maximum of 2/5 G or C at 3'end
Probe
• Tm 10°C higher than primer Tm
• 20-80% of nucleotides GC
• Length 9-40 bases
• No G on the 5' end
• <4 contiguous Gs
• Must not have more Gs than Cs
Amplicon
• 50-150bp in length
• 3' end of primer as close to the probe as possible without overlapping
Table 2.2. Conditions, which must be adhered to for design of primers and probes
using the ABI 7900™ quantitative PCR system.
58
Method for real-time PCR
1. RNA was reverse transcribed into cDNA as described in section 2.2. Reverse
transcription was performed on the Peltier Thermal Cycler (PTC-225, MJ
research).
2. The reaction components were prepared according to table 2.3. Different
reaction mixes were prepared depending on the primer/probe set used and,
therefore, the gene expression of interest. The pre-developed master mix
contained TaqMan buffer, MgCb, dNTPs and Taq polymerase.
3. 16pl of reaction mix (without the cDNA) was then added to each well of a 96
well reaction plate. Specific reaction mixes, containing different primer/probe
sets, were added to separate wells. Each plate had wells containing reaction mix
with 18s primers/probes.
4. 4pl of cDNA was then added to each well (each cDNA sample was added in
triplicate) using a separate pipette tip each time, and mixed by pipetting gently
up and down to avoid aerosol formation.
5. The plate was sealed with an optical adhesive cover and PCR was performed on
the ABI 7900. The following thermal cycler conditions were used: Initial setup-
hold at 95°C for 10 minutes; Cycle- denature at 95°C for 15 seconds,
anneal/extend at 60°C for I minute. A total of 50 cycles was preformed for each
reaction.
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gene expression assay mix
1 IX
cDNA 4 -
RNase-free water 5 -
Total 20
Table 2.3. Singleplex PCR reaction.
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Figure 2.1. TaqMan® probes and quantitative PCR. The TaqMan® probe anneals to
the corresponding CDNA. When both the fluorophore and quencher are attached there is
no fluorescence. During the subsequent PCR reaction, when the 5' nuclease activity of
the DNA polymerase separates the fluorophore from the quencher it can then fluoresce
and this can be quantified.
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2.4 EPC colony assay
Introduction
Studies to purify and characterize EPCs have been difficult due to the lack of cell
surface antigens or markers that distinguish these cells from mature vessel wall-derived
endothelial cells and from subsets of haematopoietic cells. Alternatively, EPCs can be
defined based on their different growth properties following in vitro culture of peripheral
blood. Colonies that form after 3-7 days in culture have a low proliferative potential (6
fold expansion) and are referred to as early outgrowth colony forming unit- endothelial
cell or CFU-EC. Colonies that form after 2-4 weeks exhibit a higher proliferative
potential (100 fold expansion) and are referred to as late outgrowth CFU-EC. The
EndoCult™ Liquid Medium Kit (StemCell technologies) was used to support the growth
of human EPCs from peripheral blood, and based on the established assay used by Hill
et al.
Reagents
All reagents were supplied by StemCell Technologies, unless otherwise stated.
• The EndoCult™ Liquid medium Kit included the following- basal medium and
supplements. Both are used to make EndoCult™ Liquid medium.
• Phosphate buffered saline (PBS)
• 2% fetal bovine scrum
• 3% acetic acid
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• 6-well and 24-well fibronectin-coated plates (Becton-Dickinson, Oxford, UK).
Preparation of EndoCult™ Liquid Medium
1. EndoCult™ supplements were thawed at room temperature overnight.
2. 20mls of the supplements was added to 80mls of Endocult™ basal medium, to
make a 1/5 dilution.
Method
DayO
1 EDTA anticoagulatcd blood was added to a 50ml tube. A mononuclear cell
suspension was prepared by adding an equal volume of PBS to the 50ml tube.
15ml of Ficoll-Paque® PLUS was added to a new 50ml tube. The diluted blood
sample was then carefully layered over the Ficoll. The tube was centrifuged at
1200rpm for 25 minutes, and then the buffy coat was collected into a new 50ml
tube. The mononuclear cells were resuspended in PBS and 2% FBS up to a final
volume of 40mls, followed by a further spin at 1200rpm for 7 minutes in order to
pellet the cell suspension.
2 The supernatant was decanted and 6mls of PBS/2% FBS was added to the tube.
The pellet was resuspended and transferred to a new 15ml tube. It was then spun
at 1200rpm for 7 minutes to pellet the cell suspension.
3 The supernatant was decanted and the pellet resuspended in l-3mls of
EndoCult™ Liquid Medium. Nucleated cells were counted using 3% acetic acid
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in a 1/20 dilution with the sample (eg. lOpl of cells and 190pl of acetic acid) and
counting using a haemocytometer.
4 2mls of medium was added to a 6-well fibronectin-coated dish. Each experiment
was performed in duplicate using 2 wells of a 6-well dish per sample.
5 5xl06 mononuclear cells were plated per well in the 6-well fibronectin-coated
dish in duplicate and incubated for 2 days at 37°C, 5% CCE with >95% humidity.
This step removed monocytes and mature endothelial cells.
Day2
After 2 days the mature endothelial cells and monocytes adhered to the bottom of the
well. The non-adherent cells contained the EPCs for harvesting at day2 and for further
culturing for 3 days to allow formation of endothelial colonies.
6 The non-adherent cells were collected by pipetting the medium in each well up
and down 3-4 times using a 2ml pipette.
7 These cells were then transferred into individual 5ml tubes and the volume from
each well measured using a 2ml pipette. Nucleated cells were counted as
previously described, but this time a 1/10 dilution was used (lOpl of cells and
90pl of acetic acid).
8 lxl 06 cells/well, from each well of the 6-well dish, were plated in duplicate in a
24-well fibronectin-coated dish. The dish was incubated at 37°C, 5% CCE with >
95% humidity for three days.
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At day 5 of the assay the number of colonies per well for each sample was
counted. Colonies were defined as a central core of "round" cells with elongated





Whole blood cells were phenotyped by flow cytometry using FACS-Calibur flow
cytometer (Becton-Dickinson, Oxford, UK). Cells were directly stained and analysed for
phenotypic expression of surface proteins with monoclonal antibodies (MAbs)
conjugated to phycoerythrin (PE), fluorescein isothiocynate (FITC), Peridin
Chlorophylla protein (PERCP) or Allophycocyanin (APC). The MAbs included anti-
CD34-FITC, PerCP-conjugated anti-human CD45 (Becton Dickinson, Oxford, UK).
Anti-VEGFR2-PE from (R&D systems), anti-VE-cadherin-PE from Santa Cruz
Biotechnology, and anti-CD 133-APC from Myltenyi Biotec, UK. Appropriate negative
controls (Isotype and/or no antibody) were used to establish positive stain boundaries.
lOOul of the sample was stained with the appropriate antibodies for 30 minutes in the
dark; the erythrocytes were lyscd with lysing solution (Becton Dickinson, Oxford, UK)
for 15 minutes in the dark. Afterwards the samples were centrifuged and washed with
PBS at 200g and finally the cells were fixed with Cell Fix solution (Becton Dickinson,




The principle of the ELISA is described in figure 2.2. A commercial kit was used to
perform the assay to determine VEGF levels in patients having angiography ±
angioplasty (see chapter 4) and in patients wit chronic renal failure receiving human
recombinant erythropoietin (see chapter 7) (R&D Systems, MN, USA).
Reagents
• VEGF microplate- 96 well plate coated with a mouse monoclonal antibody
against VEGF.
• VEGF conjugate- polyclonal antibody against VEGF conjugated to horseradish
peroxidase.
• VEGF standard- recombinant human VEGF165 in a buffered protein base
(2000pg/vial).
• Assay diluent RD1W- a buffered protein base.
• Calibrator diluent RD6U- animal serum.
• Wash buffer concentrate- 25-fold concentrated solution of buffered surfactant.
• Colour reagent A- stabilised hydrogen peroxide.




1 2.5ml of EDTA anticoagulated whole blood was collected from each patient/at
each time point and centrifuged for 15 minutes at lOOOxg within 30 minutes of
collection. The plasma fraction was then pipetted off and aliquoted and stored at
-20°C.
2 All reagents and samples were brought to room temperature before use. All
samples and standards were assayed in duplicate.
3 1 OOpI of diluent RD1W was added to each well.
4 1 OOpl of standard or sample was add to each well. The plate was then incubated
for two hours at room temperature.
5 Each well was aspirated then washed for a total of three times, using 400pl of
wash buffer. The plate was then inverted and blotted against clean paper towels.
6 200pl of VEGF conjugate was added to each well and the plate was incubated
for a further two hours.
7 The plate was then aspirated and washed as in step 5.
8 200pl of substrate solution was then added to each well and the plate was
incubated for 25 minutes.
9 Then 50pl of stop solution was added to each well.
10 The optical density of each well was then determined using a microplate reader
set at 450nm.
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11 The average of the duplicate readings for each standard and sample was
calculated and the average zero standard optical density subtracted.
12 A standard curve was then constructed by plotting the average absorbance for






Figure 2.2. Principle of the ELISA assay. The assay employs the quantitative sandwich
enzyme immunoassay technique. A monoclonal antibody specific for VEGF has been
pre-coated onto a microplate. Standards and samples are pipetted into the wells and any
VEGF present is bound by the immobilised antibody. After washing away any unbound
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substances, an enzyme-linked polyclonal anibody specific for VEGF is added to the
wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate
solution is added to the wells and colour develops in proportion to the amount of VEGF




Age groups, whole blood counts and differential counts passed the Kologorov- Smirnov
(KS) test of normality, and were therefore analysed using parametric tests (unpaired t-
test, paired t-test and repeated measures ANOVA with Tukey post-test analysis). All
other data, including PCR, flow cytometric, cell culture, ELISA and CRP data failed the
KS test and were analysed using non-parametric tests (Mann-Whitney U test, Wilcoxen
matched pairs test and repeated measures ANOVA with Dunn post-test analysis). The
strength of association between two quantitative variables was analysed using
Spearman's correlation coefficient (chapter 5). Where multiple paired data points were
analysed over a time course type 1 errors were a possibility. To reduce this a p value of
<0.01 was considered to be significant. Where one set of paired data was being analysed,
or when ANOVA was performed a p value of <0.05 was considered to be significant.
Results were analysed using GraphPad Instat 3 software (San Diego, CA, USA).
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3. PRELIMINARY STUDIES- PCR
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3.1. Stability of RNA in blood samples
Introduction
Each series of experiments to be described in the subsequent chapters involved the
isolation of cellular RNA from whole blood samples and reverse transcription to cDNA,
prior to performing real-time PCR. The initial isolation of RNA is critical if real-time
PCR is to be accurate. However, RNA is relatively labile and is susceptible to
degradation by ribonucleases present in blood. For optimal results, therefore, blood
samples should be processed soon after collection. To investigate this further various
pre-analytical factors were employed to assess the stability of RNA extracted from
whole blood samples.
Methods
1. 15mls (3x5mls) of EDTA anticoagulated blood were taken from each of 6
control subjects.
2. For each control subject 5mls of blood were kept at room temperature on an
agitator, 5mls of blood were kept on the laboratory bench at room temperature,
and the remaining 5mls of blood were put in the fridge at -4°C.
3. 1ml of blood was taken from each 5ml sample at the following time points:
immediately after venesection (0 hours), at 2 hours, 4 hours, 6 hours and 24
hours after venesection.
4. Total cellular RNA was then immediately extracted from each 1 ml sample,
according to the method described in section 2.1.
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5. lpg of RNA extracted from each 1ml sample was reverse transcribed using the
method in section 2.2.
6. Real-time PCR was then performed on the cDNA using Applied Biosystems
'assay-on-demand' primer/probe sets to amplify CD34, CD 133 and VEGFR-2.
Results
The results for each condition/marker are shown in figure 3.1. There was no statistically
significant change in the median RQs of CD34 mRNA from 0 hour to 24 hours in the
roller samples (p=0.56), in the room temperature samples (p=0.31) and in the 4°C
samples (p=0.81). Furthermore, there was no statistically significant change in the
median RQs of CD 133 mRNA from 0 hour to 24 hours in the roller samples (p=0.12),
from 0 hour to 6 hours in the room temperature samples (p=0.81), and from 0 hour to 24
hours in the 4°C samples (p=0.12). Finally, there was no statistically significant change
in the mean RQ values of VEGFR-2 mRNA from 0 hour to 24 hours in the roller













Figure 3.1. The median RQ values of CD34, CD133 and VEGFR-2 mRNA species
from 6 control peripheral blood samples each kept at room temperature on the bench (a),
at room temperature on a roller device (b) and at 4oC (c). Each sample was tested at
serial time points, as described in the methods section.
78
Discussion
The results presented here suggest that cellular RNA is stable over the period measured.
The most reliable data was that for the RQs of CD34 mRNA. Amplification of this
mRNA species was better in the 6 control subjects studied, compared to that of CD 133
and VEGFR-2. This is reflected in the observation that not all time points in the graphs
are represented for CD 133, and there is highly variable amplification of VEGR-2. Poor
and variable amplification is likely to be due to the relative insensitivity of the technique
in detecting the markers of EPCs in control subjects, where EPCs represent a very small
proportion of the mononuclear cell population. In spite of this, however, the results
highlight an important point, which is that is any changes in RQs of mRNA in the
patient groups tested are likely to be genuine, rather than artefactual and related to
degradation of the mRNA being measured.
There is very little published on the stability of RNA extracted from whole blood
samples. There is some data, however, on the stability of circulating RNA extracted
from plasma. Using real-time PCR, Tsui et al reported the effect of time delay in blood
processing after venesection on plasma GAPDEI mRNA concentrations [126]. 5 EDTA
samples were left at room temperature for 0, 6, and 24 hours, then the plasma was
subjected to RNA extraction. Similarly, 5 EDTA samples were left at 4°C for 0, 6 and 24
hours, following which the plasma was collected and the RNA extracted. From their
results they concluded that plasma RNA was stable over the time period studied, but that
storing samples at 4°C resulted in better RNA stability. All of the whole blood samples
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used in this thesis where RNA extraction was performed were stored at 4°C and
processed within 2 hours of collection.
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3.2. Establishing the best endogenous control
Introduction
An endogenous control is RNA or DNA that is present in each experimental sample. By
using an endogenous control as an active reference, one can normalise quantification of
an mRNA target of interest for differences in the amount of total RNA added to each
reaction. This is important when comparing the relative quantities of an mRNA target in
serial blood samples following a particular intervention. However, several studies have
indicated that the expression of traditional endogenous controls, such as GAPDH and
bcta-actin, varies among tissues and developmental stages. To ensure that the most
appropriate endogenous control would be used for our studies, an ABI TaqMan® human
endogenous control plate was used. This plate is designed to simplify the selection of
endogenous controls for gene expression studies. The plate evaluates the expression of
eleven select housekeeping genes in total RNA samples using the two-step, reverse
transcription-polymerase chain reaction (RT-PCR). The plate also features a unique
internal positive control (IPC) designed to detect the presence of PCR inhibitors in test
samples. The plate itself is an optical 96-well reaction plate divided into 12 columns,
one for every control assay. Each column consists of 8 identical wells containing
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Figure 3.2. Assay configurations of the endogenous control plate.
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Methods
1. The series of samples taken from patient 25 in the coronary angiography study
(see chapter 4) were chosen to run on the endogenous control plate. The samples
had been taken before coronary angiography, immediately after, and at 6 hours
and at 24 hours after the procedure. Total cellular RNA had previously been
extracted from the samples and stored at -80°C, according to the protocol
previously described (see section 2.1).
2. 6pg of RNA from each sample was used for reverse transcription, according to
the protocol in section 2.2, which meant that each well would receive 250ng of
RNA per sample.
3. 650pl of TaqMan Universal PCR master mix (2X) was pipetted into 4 micro
centrifuge tubes (for the 4 test samples).
4. The 4 samples were then diluted to a volume of 650pl with RNase-free water.
Each sample tube contained 150pl of cDNA.
5. The samples were then pipetted separately into the micro centrifuge tubes
containing the master mix making a total volume of 1.3mls, and the tubes were
mixed by gentle inversion.
6. The samples plus master mix were pipetted into the wells of the control plate in
50pl aliquots.
7. The wells were sealed over with an optical adhesive cover, and the plate spun to
eliminate any air bubbles.
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8. Quantitative PCR was then performed using the ABI 7900™ sequence detection
system.
Results
The pre-sample was designated the calibrator. Derivation of ACT values from the
average CT values of the calibrator and samples is the final step in comparative gene
expression analysis. The following equation describes the ACT calculation.
ACT (sample) Average CT (calibrator) — Average CT (sample)
The equation above uses the average CT of the calibrator as a baseline for evaluating
target gene expression in each sample. Samples with initial template concentrations
higher than the calibrator have lower average CT values and yield positive numbers.
Samples with lower initial template concentrations have higher average CT values and
yield negative numbers. The results of the Endogenous Control Plate are expressed in
ACT, greater than or less than the calibrator ACT. Thus, the calibrator serves as a
baseline for the assays and is shown as zero on the graph. One ACT is equal to a twofold
difference in initial template concentration. The best control is the one with the least
variation in ACT levels. Ideally, it is expressed at a constant level in all samples
regardless of cell cycle, cell type, or tissue. Because the ACT indicates the level of gene
expression relative to the calibrator, the ACT values of a good control do not vary much
from zero.
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Results for the samples from patient 25 are shown in figure 3.3. From the ACT profile
shown, the 18S ribosomal RNA (18S) phosphglycerokinase (huPGK) and P2-
microglobulin (huP2m) were shown to be good candidate control genes because their
expression remained relatively consistent across the test samples. All three assays
produced ACT values that deviated little from zero, indicating a fairly stable level of
gene expression relative to the other candidate controls. 18s was chosen as the
endogenous control, however, because of its relative abundance and ease of
amplification at relatively low cycle thresholds.
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Figure 3.3. Gene expression profile of patient 25. No bars shown for the calibrator
(ACT= 0). Blue bars represent the post-sample, brown bars represent the 6-hour sample,
and white bars represent the 24-hour sample.
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3.3. Relative quantitation of gene expression- Comparative Cj method
Introduction
Relative quantitation of RNA can be performed using the standard curve method or the
comparative method. It is relatively straightforward to prepare standard curves because
quantity is expressed relative to some basis sample, such as the calibrator. For all
experimental targets, target quantity is determined from the standard curve and divided
by the target quantity of the calibrator. Thus, the calibrator becomes the IX sample, and
all other quantities are expressed as an n-fold difference relative to the calibrator.
Because the sample quantity is divided by the calibrator quantity, the unit from the
standard curve drops out. Thus, all that is required of the standards is that their relative
dilutions are known. Any stock DNA containing the appropriate target can be used to
prepare standards. There are, however, some important points to note when performing
relative quantitation using the standard curve method.
• It is important that stock DNA is accurately diluted.
• For quantitation normalised to an endogenous control, standard curves need to be
prepared for both the target and the endogenous reference. For each experimental
sample, the amount of target and endogenous control is determined from the
appropriate standard curve. Then, the target amount is divided by the endogenous
control amount to obtain the normalised target value. Then the relative
expression levels of the target are derived using a calibrator sample, as
previously described.
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To overcome the relatively labour intensive approach of the standard curve method,
relative quantitation of RNA can be achieved using the comparative Cj method. This
uses the arithmetic formula 2~AACT to obtain RQ values. The exact derivation of the
equation is explained in the Applied Biosystems user bulletin [168]. Essentially it is the
amount of target, normalised to an endogenous control and relative to a calibrator, where
AACt is the ACt of the target minus the ACt of the calibrator. The software used by the
ABI 7900™ analyser automatically calculates these parameters. For the comparative Ct
method to be valid, however, the efficiency of the target amplification and the efficiency
of the endogenous control amplification must be approximately equal. Therefore, when
using custom designed probe and primer sets it is recommended that validation
experiments be performed to demonstrate this. Validation can be done by assessing how
the ACt of a target varies with dilution of the RNA used (see below). Fortunately, the
Applied Biosystems TaqMan gene expression assays used in our experiments have been
extensively tested and validated and found to have very similar efficiencies (close to
100%), so it is not routinely necessary to measure efficiency when using them.
However, to prove that this is the case a validation experiment was performed, using the
'assay-on-demand' primer/probe sets for CD34 and ribosomal 18s.
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Methods
1. RNA was extracted from a sample of bone marrow aspirate according to the
method described in section 2.1. The concentration of the RNA was 170ng/pl,
diluted to a working concentration of lOOng/pl.
2. Serial dilutions of the RNA were made (table 3.1) and each dilution was reverse
transcribed according to the method in section 2.2.
3. Primer/probe sets for amplification CD34 cDNA (as the target) and ribosomal
18s (as the endogenous control) were purchased from the Applied Biosystems
"assay-on-demand" service.
4. Quantitative PCR was performed using the ABI 7900™ analyser.
Results
1. The average Ct values for CD34 and 18s were obtained and the average ACT
values calculated (table 3.1).
2. The average ACT values were then plotted against the log (input RNA) to
generate a linear graph (figure 3.4).
3. The slope of the graph was calculated.
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RNA conc. Ave. CT (CD34) Ave. Ct ACt
(ng) (18s)
1000 27.81 14.35 13.46
800 28.39 14.58 13.81
600 28.14 15.31 12.83
400 29.50 15.85 13.65
200 30.92 17.51 13.41
100 31.77 18.32 13.45
Table 3.1. Average Ct value for CD34 and 18s at different RNA input amounts.
2.5
Log (input RNA)
Figure 3.4. Plot of log input RNA versus ACt.
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Conclusion
For the efficiencies of the target and endogenous control amplifications to be similar the
slope of the graph should be less than 0.1. The slope of the graph in figure 3.4 is 0.01,
confirming that the efficiencies are very similar. The AACy method of calculation of the




The coefficient of variation (cv) is a measure of dispersion of a probability distribution,
and is defined as the ratio of the standard deviation to the mean multiplied by 100 to
give a percentage value. It can be used to determine the intra- and inter-variability of a
particular assay, and can be seen as a way of assessing assay reproducibility.
Methods
Ct values for the endogenous control, ribosomal 18s, from a cohort of normal blood
samples were used to calculate the cv for the real-time PCR assay. Ribosomal 18s was
chosen because it has been shown that levels vary little between samples (section 3.2),
implying that any marked variability will be due to methodology.
1. 2.7mls of EDTA anticoagulated blood was drawn from each of 36 control
subjects.
2. Total cellular RNA was extracted from each sample, according to the method
described in section 2.1.
3. lpg of RNA extracted from each sample was reverse transcribed using the
method in section 2.2.
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4. Real-time PCR was then performed on the cDNA using the Applied Biosystems
'assay-on-demand' primer/probe set to amplify 18s. Each sample was run in
triplicate.
5. Ct values were determined for each well/sample and intra- and inter assay cvs
were calculated.
Results and discussion
See Table 3.2. The mean intra-assay cv was 2.74%. The inter-assay cv was 6.68%. Both
cv values are below 10%, which is regarded as the cut-off for acceptable assay
reproducibility. The data from real-time PCR assay used in this thesis can, therefore, be
interpreted with confidence.
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Control Ct Mean intra Ct Intra sd Intra cv
cl 8.914182
cl 8.468726
cl 8.485065 8.62265767 0.25259962 2.929486831
c2 8.323936
c2 8.500703
c2 8.431259 8.41863267 0.08905735 1.05786001
c3 7.559304
c3 7.832469
c3 7.897216 7.76299633 0.17934873 2.310302963
c4 7.115218
c4 6.975356
c4 7.419798 7.170124 0.22725135 3.169420033
c5 8.081259
c5 7.54479
c5 7.990533 7.872194 0.28714602 3.647598356
c6 8.643373
c6 8.631191
c6 8.796629 8.69039767 0.09220045 1.060946236
c7 9.939116
c7 9.842138
c7 9.376766 9.71934 0.30061419 3.092948612
c8 9.186432
c8 9.173496
c8 8.976012 9.11198 0.11792925 1.294221992
c9 8.790575
c9 8.842152
c9 8.923827 8.85218467 0.06719014 0.759023233
clO 8.939893
clO 8.804809
clO 8.046533 8.59707833 0.48154651 5.601280981
cl 1 7.813177
cl 1 8.423806
ell 8.299778 8.17892033 0.32275668 3.946201559
cl2 9.273266
cl2 9.116021
cl2 8.959337 9.116208 0.15696458 1.721818804
c 13 8.226588
c 13 8.387432
c 13 8.795276 8.46976533 0.29314773 3.461108094
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Control Ct Mean intra Ct Intra sd Intra cv
cl4 7.549772
cl4 7.611612
cl4 8.025742 7.729042 0.25880343 3.348454144
cl5 8.847471
cl5 8.508533
c 15 8.663116 8.67304 0.16968679 1.956485717
cl6 8.481077
cl6 8.501577
cl6 8.635908 8.53952067 0.08410084 0.984842612
cl7 7.74364
cl7 7.876286
cl7 8.107315 7.90908033 0.18404205 2.32697161
c 18 8.183282
c 18 7.865273
cl8 8.668533 8.23902933 0.4045213 4.90981743
cl9 8.375304
cl9 8.83628
c 19 7.853721 8.35510167 0.49159094 5.883721767
c20 8.414792
c20 7.811428
c20 7.83649 8.02090333 0.34134768 4.255726117
c21 7.354102
c21 7.266655
c21 7.34779 7.322849 0.04876766 0.665965651
c22 7.423119
c22 7.246335
c22 7.434873 7.368109 0.10562301 1.433515793
c23 8.927596
c23 8.886479
c23 8.860986 8.891687 0.03360901 0.377982365
c24 8.895221
c24 8.864418
c24 8.691408 8.81701567 0.10986433 1.246048919
c25 8.569964
c25 8.693617
c25 8.120214 8.461265 0.30176043 3.566374836
c26 8.803024
c26 8.730175
c26 8.017135 8.516778 0.43423391 5.098570274
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Control Ct Mean intra Ct Intra sd Intra cv
c27 7.901772
c27 7.700288
c27 7.702748 7.76826933 0.11562324 1.488404153
c28 8.449559
c28 8.120722
c28 8.53469 8.36832367 0.21861327 2.612390203
c29 8.427888
c29 8.1801 11
c29 8.260093 8.289364 0.12645534 1.525513223
c30 8.463441
c30 8.441451
c30 8.468628 8.45784 0.0144283 0.170590792
c31 9.3928
c31 9.523085
c31 9.496444 9.47077633 0.06883071 0.726769498
c32 8.626861
c32 8.63723
c32 8.966708 8.74359967 0.19328703 2.210611599
c33 8.010114
c33 8.231137
c33 8.73736 8.32620367 0.37282696 4.477754465
c34 9.025117
c34 9.233336
c34 8.556451 8.93830133 0.34669301 3.878734905
c35 8.112525
c35 8.605731
c35 7.840089 8.186115 0.3880896 4.740827553
c36 7.944379
c36 8.044102
c36 8.991658 8.326713 0.57801389 6.941681449
Table 3.2. Triplicate Ct values for ribosomal 18s from 36 control samples. The intra-
assay co was calculated for each triplicate result. The inter-assay cv was calculated from
the mean standard deviations (sd) of the Ct values divided by their mean, then multiplied




In order to demonstrate that the PCR products from a real-time reaction were amplicons
of CD34, CD 133 and VEGFR-2 cDNA, the proposed markers of EPCs, a
polyacrylamide gel electrophoresis (PAGE) was performed on amplified cDNA derived
from a control peripheral blood sample (figure 3.5).
Methods
RNA was extracted from the sample using the protocol described in section 2.1. lpg of
RNA extracted from the sample was then reverse transcribed using the protocol
described in section 2.2. 4pl of cDNA was then used in a real-time reaction using the
protocol and reaction conditions and appropriate primer/probe combinations described in
section2.3. 5pl of the final product was then run on 8% acrylamide gel for 45 minutes at
90 volts. The gel was then stained with ethidium bromide. A high molecular weight









Figure 3.5. PCR product run on 8% acrylamide gel. Lane 1- molecular weight marker.
Lane 2- negative control. Lane 3- CD34 band. Lane 4- CD 133 band. Lane 5- VEGFR-2
band.
Conclusions
The real-time system used in this thesis produces pure products that can be detected by
PAGE. This is reassuring and means that the PCR results in subsequent sections can be
interpreted with confidence.
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3.6. Measuring PCR product from different source materials
Introduction
There is growing interest in clinical use of locally injected autologous endothelial
precursor cells (EPC) to promote revascularisation of ischemic tissue. EPCs appear to
share many properties with haematopoietic stem cells (HSC), and sources of HSC such
as bone marrow, or HSC mobilised to peripheral blood following G-CSF administration
are becoming regarded as sources of autologous EPC for clinical use. However while
haematopoietic potential is now assessed by numbers of HSC expressing CD34, there is
no generally recognised unambiguous equivalent determinant for assessment of
vasculogenic potential.
The identification of suitable EPC sources is of the highest importance as a prerequisite
for any clinical EPC use. Freshly isolated bone marrow mononuclear cells, HSC-
mobilised peripheral blood mononuclear cells, and the CD34+ enriched or CD 133+
enriched subpopulations of these cells have been injected locally in infarcted
myocardium or ischaemic limbs with, in most cases, some recorded clinical benefit [121,
127, 128], Shi et al proposed G-CSF administration as a therapy to mobilize and
increase EPCs in circulation [4], and infusion of peripheral blood stem cells after G-CSF
administration was shown to increase vascularisation in patients after myocardial
infarction [113] and in limb ischaemia [129], In a comparative clinical trial of peripheral
blood derived EPC versus bone marrow derived EPC, implantation of both cell
preparations into infarcted myocardium gave similar positive effects showing an
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improvement in regional myocardial contractility and viability [120], While it cannot be
used for autologous EPC transplant, cord blood also has high numbers of HSCs and
these cells have been differentiated to ECs [18, 130]. Different research groups preferred
different sources of EPCs, and reports do not demonstrate any obvious advantage or
disadvantage of any source tested.
Functional assays are of utmost importance to ultimately define a real EPC phenotype.
Hill et al in 2003 have described a colony assay based on mononuclear cell colony
outgrowth on fibronectin coated plates in simple medium [12], This colony assay is
available in a standardized commercial kit which should allow inter-laboratory
comparison of results from in increasing number of studies of different clinical
conditions employing this technique [129, 131-137],
In summary, different research groups prefer different sources of EPCs, and reports do
not demonstrate any obvious advantage or disadvantage of any source tested. In this
section I have attempted to examine the different potential sources of autologous EPCs,
using real-time PCR to measure their markers, in an effort to determine which source
would provide the most plentiful supply of EPCs.
Methods
Venous blood samples (10ml) were collected from patients immediately following cell-
separator leukapheresis collection of G-CSF mobilised PBSC for autologous transplant
and from healthy donors for allogeneic transplant. Cord blood products (20-50 ml) were
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aspirated from the umbilical placental veins from normal cesarean deliveries. Bone
marrow samples (3ml) were obtained by aspiration from the posterior iliac crest of
haematologically normal donors. Peripheral blood samples were drawn form normal
controls. Two different mobilised stem cell samples, three different cord blood samples,
one bone marrow sample and two peripheral blood samples were analysed.
RNA was isolated from lml of each patient sample using the technique described
section 2.1. lOpl of the RNA was then reverse transcribed into complementary DNA
using the method in section 2.2. 4pl of cDNA was then added to each well of a 96 well
reaction plate, which then underwent RT-PCR using reaction conditions described in
section 2.3. Each sample/ primer/probe was run in triplicate and ribosomal 18s was used
as the endogenous control (figure 3.6). The primer/probe sets used were supplied off-
the-shelf from Applied Biosystems (Warrington, UK), and used to detect the following
amplicons: CD34, CD 133, VEGFR-2 (plate 1), CD 14, VE-cadherin and vWF (plate 2).
The relative quantities of these mRNA species in each sample were calculated by the
ABI software using the AACt method described in section 3.3. Results obtained were not
statistically analysed due to the small number of samples involved in this study.
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1 2 3 4 5 6 7 8 9 10 11 12
A PBl PBl PBl PB2 PB2 PB2 CB1 CBl CBl CB2 CB2 CB2
34 34 34 34 34 34 34 34 34 34 34 34
B CB3 CB3 CB3 MB1 MB1 MB1 MB2 MB2 MB2 BM BM BM
34 34 34 34 34 34 34 34 34 34 34 34
C PBl PBl PBl PB2 PB2 PB2 CB1 CBl CBl CB2 CB2 CB2
133 133 133 133 133 133 133 133 133 133 133 133
D CB3 CB3 CB3 MB 1 MB 1 MB 1 MB2 MB2 MB2 BM BM BM
133 133 133 133 133 133 133 133 133 133 133 133
E PBl PBl PBl PB2 PB2 PB2 CB1 CBl CBl CB2 CB2 CB2
V2 V2 V2 V2 V2 V2 V2 V2 V2 V2 V2 V2
F CB3 CB3 CB3 MB1 MB1 MB1 MB2 MB2 MB2 BM BM BM
V2 V2 V2 V2 V2 V2 V2 V2 V2 V2 V2 V2
G PBl PBl PBl PB2 PB2 PB2 CB1 CBl CBl CB2 CB2 CB2
18s 18s 18s 18s 18s 18s 18s 18s 18s 18s 18s 18s
H CB3 CB3 CB3 MB1 MB1 MB1 MB2 MB2 MB2 BM BM BM
18s 18s 18s 18s 18s 18s 18s 18s 18s 18s 18s 18s
Figure 3.6. The 96 well plate layout used. Two plates were constructed, the first
containing primers for CD34, CD 133 and VEGFR-2, and the second containing primers
for VE-cadherin, vWF and CD14. Key- PB1: peripheral blood-1, PB2: peripheral blood-
2, CB1: cord blood-1, CB2: cord blood-2, CB3: cord blood-3, MB1: mobilised
peripheral blood-1, MB2: mobilised peripheral blood-2, BM: bone marrow, 34: CD34,


















Figure 3.7. The mean RQ of CD34 mRNA in peripheral blood (pb), mobilised
peripheral blood (mpb) and bone marrow (bm). There is a far greater amount of CD34
mRNA in mpb and bm compared with pb. pb= 2 samples, cb= 3 samples, mpb= 2
















Figure 3.8. The mean RQ of CD 133 mRNA in peripheral blood (pb), cord blood (cb)
and mobilised peripheral blood (mpb). There is a far greater amount ofCD 133 mRNA in


















Figure 3.9. The mean RQ of VEGFR-2 mRNA in peripheral blood (pb), cord blood
(cb), mobilised peripheral blood (mpb) and bone marrow (bm). The greatest amount of
VEGFR-2 mRNA appears to be in cb, followed by bm then mpb. Peripheral blood has
the lowest relative amount of VEGFR-2 mRNA. pb= 2 samples, cb= 3 samples, mpb= 2
samples, bm= 1 sample.
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VE-cad
Figure 3.10. The mean RQ ofVE-cadherin mRNA in peripheral blood (pb), cord blood
(cb), mobilised peripheral blood (mpb) and bone marrow (bm). The greatest amount of
VE-cadherin mRNA appears to be in bm, followed by mpb then cb. Peripheral blood has
the lowest relative amount of VE-cadherin mRNA. pb= 2 samples, cb= 3 samples, mpb=
2 samples, bm= 1 sample.
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vWF
Figure 3.11. The mean RQ of vWF mRNA in peripheral blood (pb), cord blood (cb),
mobilised peripheral blood (mpb) and bone marrow (bm). The greatest amount of vWF
mRNA appears to be in mpb, followed by pb then bm. Cord blood has the lowest





pb cb mpb bm
Figure 3.12. The mean RQ of CD 14 mRNA in peripheral blood (pb), cord blood (cb),
mobilised peripheral blood (mpb) and bone marrow (bm). The greatest amount of CD 14
mRNA appears to be in pb, followed by cb then mpb. Bone marrow has the lowest




Identification and enumeration of angiogenic cells present in the adult remains difficult
and non-standardised. No single markers truly specific for endothelial cells have been
found, therefore it is necessary to utilise marker combinations to best identify CEC and
EPCs before clinical application of such cells is routine. I have attempted to measure the
mRNA levels of the markers of EPCs from the most common potential EPC sources. It
should be remembered that the number of samples studied here was small and the results
not subjected to statistical analysis. Despite this, however, all sources except normal
peripheral blood had high RQ values for CD34, CD133, VEGFR-2 and VE-cadherin
mRNA species, the putative markers of EPCs. In contrast, the RQs of vWF and CD 14
mRNA species were greater in the peripheral blood samples. These results suggest that a
source other than peripheral blood would be more appropriate as a potential source of
EPCs. My observations are similar to those of unpublished results from a collaborative
group (personal communication). They showed, using flow cytometric techniques, that
mobilised peripheral blood contained higher levels of CD34+, CD 133+ and double
positive cells. In addition, and in keeping with my results, they showed that cord blood
contained higher numbers of VEGFR-2+ cells. Most of the samples used in this thesis
were peripheral blood samples. The advantage of using such material is the relative easy
with which it can be obtained compared with cord blood or mobilised peripheral blood.
The disadvantage, however, is the relative paucity of EPC mRNA in such material. This
may explain, in part, the difficulty I have had with reproducibility of triplicate RQ
values for a sample, particularly when CD 133 probe/primer sets were used.
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4. ENDOTHELIAL PROGENITOR CELLS AND ISCHAEMIC HEART DISEASE
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4.1. Introduction
Ischaemic heart disease is a major cause of morbidity and mortality worldwide. Despite
advances in percutaneous coronary intervention (PCI), major adverse cardiac events
occur in 30% of patients following balloon angioplasty and 20% following stenting
[138], Vascular trauma, induced by percutaneous intervention, initiates a sequence of
events in which the release of cytokines and growth factors result in the proliferation of
smooth muscle and deposition of platelets and leucocytes at the site of injury,
accelerating vascular repair. Endothelialisation is necessary to prevent mural thrombus
formation and neointimal hyperplasia, which may result in peri-procedural ischaemic
complications or restenosis.
The discovery by Asahara and colleagues that mononuclear cells in peripheral blood
have the potential to differentiate into endothelial cells has launched a new field of
cardiovascular research [3], Endothelial progenitor cells (EPCs) have been characterised
by their expression of both haematopoietic (CD34) and endothelial cell antigens (CD 133
and VEGFR-2), and by their ability to proliferate, migrate and differentiate into mature
cell types. These putative EPCs form vascular structures in vitro and are incorporated
into the vessel wall in experimental models of ncovascularisation [130], The traditional
paradigm of vascular repair is based on the proliferation and migration of pre-existing
mature endothelial cells from adjacent vasculature [139]. The discovery of circulating
progenitors has altered our view of this process, with progenitor cells potentially playing
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an important role in the maintenance and repair of the vascular endothelium and in the
pathogenesis of atherosclerotic plaque formation and its consequences.
EPCs can be isolated and cultured from a variety of cell populations in peripheral blood
and bone marrow, but as yet no definitive phenotype has been ascribed to EPCs.
Comparisons between clinical studies have been limited by the use of a variety of
phenotypic markers to discriminate EPCs and by the lack of comparable functional
assays. In the face of an uncertain phenotype, the EPC colony forming unit assay (CFU-
EPC) has emerged as an alternative specific enumeration system for EPCs [12].
Increasingly, groups quantify phenotypic EPCs or functional CFU-EPCs, however few
clinical studies report both or comment on the relationship between phenotypc and
function.
EPCs are infrequent in peripheral blood, but numbers have been shown to increase
rapidly in response to myocardial ischaemia and acute myocardial infarction (table 1.2)
[105, 140], Reduced numbers of EPCs have been demonstrated in cigarette smokers
[64], patients with diabetes mellitus [141], and in those with evidence of endothelial
dysfunction [142], These patients are at high risk of complications following PCI.
Furthermore, patients with diffuse in-stent re-stenosis have reduced EPC number and
function in comparison with matched controls at the time of presentation [61].
Inadequate EPC number and function prior to angioplasty, as well as inadequate early
and sustained EPC recruitment may favour a maladaptive response to arterial injury and
result in an increased incidence of in-stent thrombosis, re-stenosis and ischaemic
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complications. The immediate effects of local vascular injury during angioplasty and
stenting on the mobilization of EPCs are not known. The aim of this part of the thesis
was to measure circulating EPCs (using PCR and flow cytometry) and functional CFU-
EPCs following PCI in patients with stable coronary disease.
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4.2 Methods
Forty patients undergoing elective coronary angiography participated in this study,
which was performed with the approval of the local research ethics committee. Written
informed consent was obtained from all volunteers. All patients were recruited from the
Medical Day Case Unit at the Royal Infirmary, Edinburgh following referral for
diagnostic angiography to investigate symptoms suggestive of stable angina. Patients
with a recent acute coronary syndrome or coronary intervention (<3 months), renal or
hepatic failure, or a systemic inflammatory disorder or malignancy were excluded from
the study. Twenty patients underwent diagnostic coronary angiography alone, and 20
required balloon angioplasty and stenting because of flow limiting coronary stenosis
(table 4.1).
All patients were treated for two weeks with 75 mg clopidogrel prior to angiography or
PCI. Coronary angiography was performed via right femoral or radial artery approach
with 6F arterial catheters. Elective PCI was performed in all patients after 7,500 IU
intravenous heparin administration and in one patient after intravenous glycoprotein
Ilb/IIIa inhibitor. Coronary stents (Liberte, Boston Scientific) were implanted in all





Age (years) 62 ±2 59 ±3
Sex (male/female) 11/9 14/6
Cigarette smokers 4 3
Diabetes mellitus 7 2
Hypertension 12 12
Previous MI 2 3
Previous PCI 1 7
Prior CABG 0 1
Total cholesterol (mg/dL) 90±7 81±9
LDL-cholesterol (mg/dL) 47±18 43±9
HDL-cholesterol (mg/dL) 22±9 22±2
Triglycerides (mg/dL) 45±5 40±5
Fasting glucose (mg/dL) 151±18 99±40
C-reactive protein n.a. n.a.
Number of diseased vessels
Minor plaque only 12 0
1 vessel disease 0 9
2 vessel disease 4 8
3 vessel disease 4 3
Stent implantation
De novo lesion 0 17
Restenosis 0 3
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Table 4.1. Clinical characteristics and angiographic findings of patients undergoing
diagnostic angiography or percutaneous coronary intervention (values are presented as
number or mean ± SEM).
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A venous cannula (17-gauge) was inserted into a large subcutaneous vein of the ante-
cubital fossae for blood sampling before, immediately after and at 6 and 24 hours
following angiography. EDTA anti-coagulated blood (Sarstedt-Monovette, Germany)
was collected for real-time PCR, flow cytometry and for preparation of plasma for assay
of VEGF by ELISA. In 24 subjects (12 diagnostic angiograms and 12 PCI), 20 mL of
whole blood was drawn at baseline and 24 hours for mononuclear cell preparation and
cell culture. Whole blood was analysed for total cells, differential count and platelets
using an autoanalyzer (Sysmex, UK). Plasma Troponin 1 concentrations were measured
using an automated immunometric assay (method not described) (Ortho-clinical
Diagnostics, High Wycombe, UK). Serum was prepared for measurement of C-reactive
protein (CRP) concentrations using an immunonephelometric assay (method not
described) (Bchring BN II nephelometer, Marburg, Germany).
RNA isolation
Total leukocyte RNA extraction from 1 mL of whole blood was performed using
Qiagen's RNeasy Mini Kit (Qiagen Ltd., Crawley, UK) (section 2.1). RNA
concentration and purity were estimated by UV absorbance at 260 and 280 nm. The
260:280 nm ratios were all greater than 1.8 indicating that little protein contamination
was present. One microgram of total RNA was transcribed into cDNA (section 2.2) in
each reverse transcription reaction with 200 units ofM-MLV reverse transcriptase for 60
minutes at 37°C in 20 pL reactions containing 1 pL (0.5pg/pl) of random hexamer
primers, with 0.625 pL (40 units/pL) of RNase inhibitor, 5 pL of dNTP mix (containing
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dATP, dCTP, dGTP and dTTP, each at a concentration of 10 nM in water) and 5 pL of
5X RT reaction buffer (containing 50 mM Tris-HCL-pH 8.3 at 25°C, 75 mM KCL, 3
mM MgCE and 10 mM DTT).
Real-time PCR
Real-time PCR was carried out using the ABI Prism ©7900HT system (Applied
Biosystems, Warrington, UK) to determine the relative quantity (RQ) of mRNA for
selected genes (section 2.3). RQ can be defined as a comparison of a target signal in
different samples to a reference sample and normalised to an endogenous control. PCR
primers and probes for amplification of cDNA derived from CD34, CD 14, VE-cadherin
and vWF transcripts were obtained from Applied Biosystems (Foster City, CA, USA).
Each assay contained forward and reverse PCR primers (final concentration of 900 nM
each) and one TaqMan MGB probe (6-FAM dye-labelled, to a final concentration of 250
nM). All primer-probe sets had been quality control checked and validated. The
ribosomal 18s gene was used as an internal control. 4 pL of the reverse transcription
reaction was analysed in each PCR reaction. The PCR reactions were run in triplicate in
20 pL assays, each containing cDNA, 1 pL of primer/probe, 10 pL of universal PCR
master mix and distilled water. The cycling program was as follows: (a) initial activation
for 10 minutes at 95°C; (b) 50 amplification cycles with a 15 second denaturing step at
95°C, and a 1 minute combined annealing and extension step at 60°C. Analysis was
performed using ABI 7900HT SDS software (version 2.1), in order to obtain the relative
quantities (RQ) ofmRNA compared to a calibrator.
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Flow cytometry
Whole blood cells were phenotyped by flow cytometry, according to the protocol in
section 2.5. Cells were directly stained and analysed for phenotypic expression of
surface proteins using anti-human monoclonal antibodies (MAbs) conjugated to
phycoerythrin (PE), fluorescein isothiocynate (FITC), or Peridin Chlorophylla protein
(PerCP). The MAbs used were anti-CD34-FITC, anti-CD 133-APC (Myltenyi Biotec,
UK), anti-CD45-PerCP, (Becton Dickinson, Oxford, UK), anti-VEGFR2-PE (R&D
systems, Minneapolis, USA) and anti-VE-cadherin-PE (Santa Cruz Biotechnology).
Appropriate negative controls (isotype and/or no antibody) were used to establish
positive stain boundaries. Undiluted samples (lOOpL) were stained with antibodies for
30 minutes in the dark. Erythrocytes were lysed (lysing solution, Becton Dickinson), and
samples were centrifiiged at 200 g for 10 minutes, washed with phosphate buffered
saline, and fixed (Cell Fix solution, Becton Dickinson). For each sample, 50,000 events
were acquired in the leucocyte region (as determined by characteristic forward and side
scatter profile), using a FACS Calibur flow cytometer (Becton Dickinson) and data were
analysed using FCS Express (DeNovo Software). EPCs were quantified from the total
white cell count at a given time point and based on the percentage of cells expressing the




Mononuclear cells were isolated by Ficoll density gradient separation, washed twice
with PBS and resuspended at 2.5x106/mL in Complete Endothelial Culture Medium
(CECM) (comprising EndoCult Basal Medium supplemented with 1/5 dilution of
EndoCult supplements, Stem Cell Technologies, UK). 2 mL of cell suspension was
placed into each of 6-well Fibronectin-coated plates (Becton Dickinson) and incubated
at 37°C, 5% CO2 with 95% humidity (see section 2.4). After two days, mature
endothelial cells and monocytes remain adhered to the bottom of the well and non¬
adherent cells, containing EPCs, were transferred to a fibronectin-coated 24-well plate
(Becton Dickinson) at lxl06/well for three days at 37°C, 5% CO2 with 95% humidity.
Colonies (CFU-EPC, early outgrowth colony forming unit endothelial progenitor cell;
Stem Cell Technologies) were defined as a central core of "round" cells with elongated
"sprouting" cells at the periphery and were counted on day 5 in a minimum of four wells
by observers unaware of the subjects' clinical profiles. In order to confirm endothelial-
ccll lineage, direct staining was performed on colonies using (Fluorochrome-) acetylated
LDL and co-stained with (Fluorochrome-) Lectin (Ulex europaeus I agglutinin).
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ELISA
Plasma was extracted from EDTA anticoagulated blood samples at baseline and 6 hours
after the procedure in patients undergoing angiography alone and those having both
angiography and angioplasty. The concentration of VEGF in each sample was then
determined by ELISA according to the protocol in section 2.6.
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4.3. Results
There were no complications arising from angiography or PCI and all patients (Table
4.1) were discharged home 24 hours after procedure.
Systemic inflammatory response
Results are shown in table 4.2 and depicted graphically in figures 4.1-4.5. Diagnostic
angiography alone did not increase the mean peripheral blood leucocyte count (figure
4.1b), neutrophil count (figure 4.2b), lymphocyte count (figure 4.3b) monocyte count
(figure 4.4b) or the median serum C-reactive protein concentration (figure 4.5b).
Coronary intervention increased the mean total leucocyte count (7.0±0.36x 109/1 to
8.2±0.34x109/1, p<0.005, figure 4.1c), the mean neutrophil count (4.36±0.3 Ixl09/1 to
5.73±0.31xl09/l, p<0.005, figure 4.2c), and median serum C-reactive protein
concentration (l.lmg/1 to 3.1mg/l, p<0.005, figure 4.3c) at 24-hours. There was an
apparent transient reduction in the mean monocyte count immediately following
coronary intervention (0.57±0.03xl09/l to 0.48±0.04x 109/l, p<0.01, figure 4.4c), with a
return to pre-procedure levels by 24 hours. Finally, there was no evidence of significant
myocyte necrosis 24 hours following diagnostic angiography or PCI (table 4.2).
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Pre-procedure Post-procedure 6 hours 24 hours
Angiography
WBC (x 109/L) 7.94±0.45 7.28±0.37 7.63±0.37 6.28±0.37
Neutrophils
(X109/L) 4.54±0.34 4.72±0.32 4.59±0.26 3.72±0.25
Lymphocytes
(X109/L) 2.07±0.14 1.84±0.13 2.19±0.17 1.75±0.16
Monocytes
(X109/L) 0.61±0.04 0.49±0.03 0.63±0.06 0.59 ±0.09
C-reactive
protein (mg/1)
3.62 - - 4.66
Troponin I (g/L) 0.20 ±0.01 - - 0.20 ±0.01
PCI
WBC (x 109/L) 7.0 ±0.36 6.66 ±0.3 7.07 ±0.2 8.2 ±0.34*
Neutrophils
(x 109/L) 4.36 ±0.31 3.97 ±0.29 4.39±0.23 5.73 ±0.31*
Lymphocytes
(xl09/L) 1.81 ±0.1 1.73 ±0.12 1.89 ± 0.14 1.71 ±0.11
Monocytes
(X109/L) 0.57 ±0.03 0.48 ±0.04** 0.57 ±0.03 0.56 ±0.03
C-rcactive
protein (mg/1)
1.14 - - 3.14*
Troponin I (g/L) 0.20 ±0.01 - - 0.40 ±0.11
Values are presented as mean ± SEM, except CRP where values are presented as
median; pre-procedure versus time point, *P<0.005, **P<0.01.
Table 4.2. Markers of inflammation and myocyte necrosis following diagnostic
angiography or percutaneous coronary intervention.
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Figure 4.1. Change in the mean total white cell count (WBC±sem) in (a) all patients
undergoing angiography ± angioplasty, (b) in patients undergoing angiography only, and
(c) in patient undergoing angiography plus angioplasty. There was a significant increase
in the total WBC in all patients by 24 hours after the procedure (7.25±0.28 to
7.41±0.3xl09/l, p<0.05 by ANOVA) (a). This increase was confined to those patients
undergoing angiography plus angioplasty (7.00±0.36 to 8.20±0.34xl09/l, p<0.001 by
ANOVA) (c).
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Figure 4.2. Change in the mean neutrophil count in (a) all patients undergoing
angiography ± angioplasty, (b) in patients undergoing angiography only, and (c) in
patient undergoing angiography plus angioplasty. There was a significant increase in the
neutrophil count in all patients by 24 hours after the procedure (4.45±0.23 to
4.90±0.69x109/1, p<0.05 by ANOVA) (a). This increase was confined to those patients
undergoing angiography plus angioplasty (4.36±0.39 to 5.73±0.31xl09/l, p<0.001 by
ANOVA) (c).
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Figure 4.3. Change in the mean lymphocyte count in (a) all patients undergoing
angiography ± angioplasty, (b) in patients undergoing angiography only, and (c) in
patient undergoing angiography plus angioplasty. There was a significant decrease in the
lymphocyte count in all patients immediately after the procedure followed by a recovery
in the count by 6 hours and then a decrease again by 24 hours after the procedure
(1.94±0.08 to 1.78±0.08 to2.03±0.14 to 1.72±0.74xl09/l, p<0.05 by ANOVA) (a). There
was no significant change in the mean lymphocyte count when control and intervention
groups were analysed (a & b).
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Change in monocyte count -ail patients
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Monocyte count -intervention
Figure 4.4. Change in the mean monocyte count in (a) all patients undergoing
angiography ± angioplasty, (b) in patients undergoing angiography only, and (c) in
patient undergoing angiography plus angioplasty. There was a significant decrease in the
monocyte count in all patients immediately after the procedure followed by a recovery in
the count by 6 hours (0.59±0.02 to 0.49±0.02 to 0.61±0.03xl09/l, p<0.005 by ANOVA)
(a). This change was confined to those patients undergoing angiography plus








Figure 4.5. Change in the median CRP level in (a) all patients undergoing angiography
± angioplasty, (b) in patients undergoing angiography only, and (c) in patient
undergoing angiography plus angioplasty. There was a significant increase in the CRP
level in all patients immediately by 24 hours after the procedure (1.83 to 3.35mg/l,
p<0.001) (a). This increase was confined to those patients undergoing angiography plus
angioplasty (1.14 to 3.14mg/l, p<0.005) (c).
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PCR
The results of the effect of angiography ± PCI on messenger RNA levels are presented
in table 4.3, and depicted graphically in figures 4.6-4.11, There was a significant
reduction in the median RQ of CD34 mRNA immediately following procedure in those
patients undergoing diagnostic angiography only, with a recovery to baseline levels by 6
hours after the procedure (1.71 to 1.17, p<0.005, figure 4.6b). In addition, there was a
significant reduction in the median RQ of VEGFR-2 mRNA by 6 hours following the
procedure in the group undergoing angiography only (9.93 to 8.82, p<0.005, figure
4.8b) (b). Furthermore, there was a significant reduction in the median RQ of VE-
cadherin mRNA immediately following the procedure, followed by a return to baseline
levels by 6 hours in those patients undergoing angiography plus angioplasty (1.18 to
0.77, p<0.001, figure 4.9c). Finally, there was a significant reduction in the median RQ
of CD14 mRNA immediately following the procedure in the group undergoing
angiography only (2.94 to 2.05, p<0.01, figure 4.11b). There was also a significant
reduction in the median RQ of CD 14 mRNA immediately following the procedure, with
a return to baseline then an increase by 24 hours in the group undergoing angiography
plus angioplasty (2.82 to 1.90 immediately post to 3.13 by 24 hours, p<0.05 by
ANOVA, figure 4.11c).
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Values relative quantities (median iinterquartile ranges); pre-procedure versus time point, *P<0.005,
**P<0.01, ***P<0.001
Table 4.3. Leucocyte rnRNA levels following diagnostic angiography or percutaneous
coronary intervention
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CD34 mRNA- all patients
CD34 mRNA- control patients
136
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Figure 4.6. Changes in the relative quantity (RQ) of CD34 mRNA in (a) all patients
undergoing angiography ± angioplasty, in (b) patients undergoing angiography only and
in (c) patients undergoing both angiography and angioplasty. There was a decrease in
the median RQ of CD34 mRNA immediately following the procedure when all patients
were analysed (a). This decrease was confined to patients undergoing angiography only
(P<0.005) (b).
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CD133 mRNA- all patients
CD133 mRNA- control patients
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CD133 mRNA- PCI patients
C.
Figure 4.7. Changes in the relative quantity (RQ) of CD133 mRNA in (a) all patients
undergoing angiography ± angioplasty, in (b) patients undergoing angiography only and
in (c) patients undergoing both angiography and angioplasty. There was no significant
change in the median RQ ofCD 133 mRNA following angiography and angioplasty.
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VEGFR-2 mRNA- PCI patients
C.
Figure 4.8. Changes in the relative quantity (RQ) of VEGFR-2 mRNA in (a) all
patients undergoing angiography ± angioplasty, in (b) patients undergoing angiography
only and in (c) patients undergoing both angiography and angioplasty. There was a
significant reduction in the RQ of VEGFR-2 mRNA immediately following the
procedure in the group undergoing angiography only (p<0.005) (b).
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VE-cadherin mRNA- all patients
VE-cadherin mRNA- control patients
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VE-cadherin mRNA- PCI patients
Figure 4.9. Changes in the relative quantity (RQ) of VE-cadherin mRNA in (a) all
patients undergoing angiography ± angioplasty, in (b) patients undergoing angiography
only and in (c) patients undergoing both angiography and angioplasty. There was a
significant reduction in the RQ of VE-cadherin mRNA immediately following the
procedure with a return to baseline levels by 24 hours when all patients were analysed
(p<0.005, by ANOVA) (a). This change was confined to the group undergoing
angiography plus angioplasty (p<0.005) (c).
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C.
Figure 4.10. Changes in the relative quantity (RQ) of vWF mRNA in (a) all patients
undergoing angiography ± angioplasty, in (b) patients undergoing angiography only and
in (c) patients undergoing both angiography and angioplasty. There was a significant
reduction in the RQ of vWF mRNA immediately following the procedure and by 6
hours when all patients were analysed (p<0.0l) (a). Flowever, no significant changes
were found when the data was analysed according to intervention.
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CD14 mRNA- control patients
146
CD14 mRNA- PCI patients
Figure 4.11. Changes in the relative quantity (RQ) of CD 14 mRNA in (a) all patients
undergoing angiography ± angioplasty, in (b) patients undergoing angiography only and
in (c) patients undergoing both angiography and angioplasty. There was a significant
reduction in the median RQ of CD 14 mRNA immediately following the procedure
followed by an increase and return to baseline by 24 hours when all patients were
analysed (p<0.01 by ANOVA) (a). There was a significant reduction in the median RQ
of CD 14 mRNA immediately following the procedure in the group undergoing
angiography only (p<0.01) (b). There was a significant reduction in the median RQ of
CD 14 mRNA immediately following the procedure, with a return to baseline then an




Results are shown in table 4.4. No increase was observed in the number of
CD34+VEGFR-2+ cells following the procedure in patients undergoing angiography
alone or with angioplasty. In addition no correlation was found between EPCs identified
by phenotype and the number of functional EPCs quantified using cell culture (CFU-









0.100±0.019 0.082±0.015 0.087±0.016 0.102±0.028
CD34+VEGFR-2+
cells (% leucocytes)
0.030±0.010 0.020±0.005 0.021±0.004 0.026±0.007
CD34+ cells (xlOVml
blood)
6.54±0.92 5.43±0.80 5.98±0.81 5.67±1.15
CD34+VEGFR-2+
cells (xlO'Vml)




0.083±0.011 0.105±0.011 0.091±0.012 0.083±0.010
CD34+VEGFR-2+
cells (% leucocytes)
0.019±0.003 0.029±0.006 0.020±0.004 0.021 ±0.004
CD34+ cells (xl03/ml
blood)
5.40±0.61 7.00±0.82 6.33±0.84 6.55±0.76
CD34+VEGFR-2+
cells (xlO'Vml)
1.15±0.19 1.91±0.47 1.28±0.29 1,65±0.36
Table 4.4. Circulating CD34+ and CD34+VEGFR-2+ cells following angiography or




Results are shown in figures 4.20-4.22. Mononuclear cells plated on fibronectin formed
typical colony forming units (CFU-EPCs), characterized previously as a central cluster
of rounded cells surrounded by radiating thin, flat cells [12]. Although unaffected by
diagnostic angiography, the number and cellularity of CFU-EPCs were increased 24
hours after PCI (from 0.02 to 0.08 xlO4 cells plated, p<0.01, figures 4.20&4.22). Direct
staining confirmed that CFU-EPCs, like mature endothelial cells, bind lectin and
integrate acetylated-LDL. The majority of both small round cells and spindle shaped
cells expressed CD14 (figure 4.21).
Figure 4.20. Phase contrast pictures illustrate a typical CFU-EPC before (a) and 24
hours after coronary angioplasty and stenting (b).
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Figure 4.21. Micrographs of CFU-EPC with direct staining; solitary spindle-shaped
cells from CFU-EPC assay stained for ac-LDL (green) (a) solitary spindle-shaped cells
(b) and CFU-EPC colonies (c) stained for ac-LDL (green) and CD 14 (orange); CFU-








Figure 4.22. Number of CFU-EPCs before and 24 hours after the procedure in (a) all
patients undergoing angiography ± angioplasty, (b) in patients undergoing angiography
only, and (c) in patient undergoing angiography plus angioplasty. There was a
significant increase in the number of CFU-EPCs in those patients undergoing
angiography plus angioplasty (0.02 to 0.08 per 104 cells, p<0.01) (c).
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ELISA
Results are shown in figure 4.23. The median concentration of VEGF was significantly
higher by 6 hours after the procedure in patients undergoing angiography plus
angioplasty (27 to 34.25pg/ml, p<0.005, figure 4.23a). However, there was no
significant change in the median concentration of VEGF in patients undergoing
angiography alone (40 to 38.9pg/ml, p=0.41, figure 4.23b).
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VEGF- PCI patients
Figure 4.23. VEGF levels at baseline and 6 hours after the procedure in patients having
angiography and angioplasty (a), and in patients having angiography only (b).
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4.4 Discussion
It has been demonstrated in this study that PCI, but not diagnostic angiography, is
associated with a mild systemic inflammatory response and an increase in functional
CFU-EPCs in the peripheral blood. However, there was no associated increase in CD34,
CD 133 or VEGFR-2 mRNA species and no increase in the number of CD34+ or
CD34+VEGFR-2+ cells. In this clinical model of acute vascular injury, it is possible that
the acute response to injury is mediated by more mature EPCs (CFU-EPC) rather than
the primitive CD34+, CD 133+ VEGFR-2+ cells that have hitherto been considered as
the major endothelial progenitor cell source in blood and bone marrow. Circulating
CD34+, CD133+, VEGFR-2+ cells may ultimately be capable of endothelial cell
differentiation, but are rare in peripheral blood. Moreover, the data presented here does
not support the idea that these cells are mobilised rapidly in response to acute vascular
injury and are responsible for CFU-EPC.
CFU-EPC are reduced in those with cardiovascular risk factors and evidence of vascular
impairment, raising the possibility that a limited EPC reserve may contribute to a
maladaptive response to vascular injury and predispose to atheroma formation [12].
Previous studies have demonstrated early mobilisation of EPCs following vascular
injury in patients with acute myocardial infarction [140], major burns and following
CABG surgery [33]. These clinical events involve extensive damage to a number of
tissues in addition to the vasculature, which may contribute to the mobilisation of
progenitors. This study extends this by showing that local, selective vascular injury can
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influence the number of circulating progenitor cells, and provides a rational for the
therapeutic mobilisation of EPCs at the time ofPCI to influence outcome.
Current strategies to reduce the incidence of complications following percutaneous
intervention are based on suppressing cellular proliferation rather than enhancing
vascular repair. Vessel injury during PCI exposes underlying collagen and tissue factor,
activating platelets and the coagulation cascade, and may result in acute or sub-acute
stent thrombosis [143]. In the absence of an intact endothelium, local platelet/platelet
and platelet/leukocyte complexes form, and persistent inflammation encourages smooth
muscle hypertrophy and in-stcnt restenosis. Drug eluting stents have dramatically
reduced the incidence of early in-stent restenosis [144], but local anti-proliferative
therapy may interfere with vascular healing and prevent formation of a functional
endothelial layer [145], In experimental studies, transfusion of EPCs following vascular
injury prevents both thrombus formation and neointimal proliferation [146], Indeed,
patients with diffuse in-stent restenosis have reduced numbers of circulating EPC in
comparison with matched controls [61]. Stents coated with antibody to CD34 may
encourage seeding of the stent and early endothelium formation and in feasibility studies
have been safely deployed in man [147].
Coronary intervention increased the number of CFU-EPCs, but was not associated with
a mobilisation of cells expressing CD34 and VEGFR-2, either at the molecular or
phenotypic levels. These findings initially appear discordant and require further
discussion. The original description of the putative endothelial progenitor cell was based
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on cell culture and adhesion techniques. Asahara et al. described a population of adult
human circulating CD34+ cells that could differentiate into cells with endothelial-like
characteristics in vitro [3], The exact origin and phenotype of these progenitors remains
a matter of debate in part because the purity ofCD34' cells used in this initial study was
only 15% [3], Subsequently the co-expression of transmembrane glycoproteins CD34,
CD 133 and VEGFR-2 has been used in an increasing number of clinical studies to
phenotype and quantify circulating endothelial progenitor cells.
As the field has developed, an increasing number of methods have emerged to define
vascular progenitors and quantify regenerative capacity. The CFU-EPC assay used to
quantify the number of circulating functional endothelial progenitors in this study has
been used widely since it was described by Hill et al. [148], Whilst quantification of
CFU-EPC provides an accurate measure of the capacity of circulating mononuclear cells
to form endothelial cells, it is doubtful whether these colonies primarily arise from the
CD34+ stem cells. No correlation between the number of peripheral blood CD34+ cells
and the number of CFU-EPCs was found in this study (see results section). Studies
addressing the origin of endothelial progenitor lineage in adult peripheral blood have
demonstrated that monocytes also express endothelial lineage markers such as VEGFR-
2 and can differentiate into mature endothelial cells [23]. Rehman et al. found that the
majority of CFU-EPCs expressed monocyte markers such as CD 14, Mac-1, and CD1 lc,
suggesting that peripheral-blood endothelial-like cells are derived from
monocytes/macrophages [24], The concept that functional endothelial cells may
originate from a CD 14* expressing progenitor is supported by reports that mature
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endothelial cells isolated from human umbilical vein express CD 14 [149], Furthermore,
Urbich et al. demonstrate that isolated CD 14' cells also have the capacity to improve
neovascularisation after hind limb ischemia [150].
Direct staining of our colonies demonstrates that CFU-EPCs behave like mature
endothelial cells and incorporate acetylated LDL, but also confirmed that these cells
strongly express CD 14. In keeping with recent reports unpublished observations show
that isolated CD341 cells do not give rise to spontaneous CFU-EPC but instead die in
this assay: in contrast, all CFU-EPC activity is found in CD141 enriched, but not in
CD 14' depleted, fractions of peripheral blood mononuclear cells [25, 151]. This
population of circulating CD 14' monocytes appear more functionally mature than
CD34+ cells, are ready to home to sites of vascular injury, and are more abundant in
normal peripheral blood than in bone marrow. In contrast, while CD34+, CD133+,
VEGFR-2+ cells may ultimately give rise to endothelial cells, they are much less
prevalent in peripheral blood than in bone marrow, and may only be the precursors of
the more functionally mature CFU-EPC-capable cells that appear more crucial for an
immediate response to vascular injury.
Whilst measurement of CD 14+ monocytes by flow cytometry was not performed, total
leucocyte CD 14 mRNA and monocyte numbers were quantified. It was found that there
was a significant and reproducible decrease in both immediately after catheterisation in
the patient group having angiography plus PCI. It is possible that these cells
immediately localise to the site of vessel damage - both at the site of femoral arterial
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puncture and at the site of coronary angioplasty and stenting. This may also explain the
reduction in other molecular and phenotypic markers immediately following the
procedure (see results section). The number of peripheral blood monocytes was restored
to prc-procedural levels by 24 hours, and CD 14 mRNA levels significantly increased by
24 hours after PCI. Mobilisation of CD 14* monocyte-like cells may explain the increase
in CFU-EPC in peripheral blood observed 24 hours after arterial injury. These cells may
contribute to vascular repair either through formation of mature endothelial cells and
incorporation into the vessel wall, or through the release of angiogenic growth factors at
the site of vessel injury. Further studies are required to confirm these observations and to
explore specifically the role ofCD141 monocytes in vascular injury and repair.
In considering the therapeutic potential of mobilised stem cells and stents with cell
specific antibodies, it should be acknowledged that the process of vessel injury and
repair is a complex one. It has been demonstrated that there is an early increase in
circulating neutrophils at 24 hours, and others have observed a later rise in monocyte
numbers 48 hours following PCI [152], These clinical observations mirror the findings
of Wilcox ct al. who demonstrated in a porcine angioplasty model an early influx of
neutrophils into the adventitia of the site of vessel injury at 6-24 hours, and the later
incorporation of monocytes at 72 hours [153]. Interestingly, Fukuda et al., found a
strong correlation between circulating monocyte numbers and in stent restenosis [152].
It is likely that circulating monocytic cells contains sub-populations of bone marrow
derived progenitor cells that may contribute to both re-endothelialisation and neointimal
formation. Autologous cell therapy with unselected mononuclear cells has the potential
159
to affect outcome adversely, with a recent study by George et al. suggesting that
repeated intravenous treatment with bone marrow derived mononuclear cells may
actually increase atheroma formation and reduce plaque stability [154].
It is likely that a variety of host factors and persistent localised inflammation will dictate
whether endothelialisation or neointimal expansion will ensue following PCI. Previous
studies have reported a systemic inflammatory response to the vascular injury associated
with percutaneous coronary intervention, with serum IL-6, CRP and SAA levels
elevated following intervention [155], Elevated pre-procedural CRP-levels predict
adverse outcome after coronary stent implantation and are associated with a greater
degree of angiographic restenosis, suggesting systemic inflammation is associated with a
proliferative response [156], Mechanical injury of the atherosclerotic plaque by balloon
inflation triggers local inflammatory mechanisms with leucocyte adhesion, activation
and cytokine release [157], The mobilisation of neutrophils and increase in CRP
concentrations observed following PCI, are presumably systemic manifestations of this
local inflammatory response to arterial injury. Finally the increased VEGF expression
only in patients with local vascular injury following PCI (figure 4.23a) is consistent
with other studies showing that EPC mobilization is cytokine driven [31].
4.5. Conclusion
Local vascular injury following angioplasty and stcnting results in a mild systemic
inflammatory response and increases the number of CFU-EPCs. Circulating
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CD34+VEGFR-2+ cells are rare in peripheral blood, and are not mobilised rapidly in
response to vascular injury. Therefore, the acute response to injury may be mediated by
more mature EPCs (CFU-EPC) rather than the primitive CD34+VEGFR-2+ cells that
have hitherto been considered as the major endothelial progenitor cell source in blood
and bone marrow. A better understanding of the cellular response to vascular injury is
necessary to allow a more sophisticated approach to reducing the complications of
percutaneous coronary intervention with new strategies designed to enhance vessel
repair.
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5. ENDOTHELIAL PROGENITOR CELLS AND AORTIC ANEURYSM REPAIR
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5.1 Introduction
The recent identification of circulating stem cells capable of differentiating into
endothelial cells has lead to a re-evaluation of our understanding of how the vascular
endothelium is repaired [3]. The long held theory that endothelium could only be
replaced by the proliferation of existing mature endothelium has been extended to
include the process of vasculogcnesis from a stem cell population. These stem cells
(endothelial progenitor cells, EPCs) have been identified in a variety of tissues,
including endothelium, and can be isolated from peripheral blood and bone marrow
[158]. In animal models of tissue ischaemia, heterologous and autologous, EPCs derived
from blood and bone marrow have been shown to incorporate into sites of vascular
damage and neovascularisation [3, 5, 6]. Furthermore, autologous transplantation of
mononuclear cells containing EPCs have been used therapeutically to good effect in
patients with ischaemic myocardium and peripheral ischaemia [110, 112]. It is known
that EPCs are mobilised from the bone marrow in response to vascular injury and tissue
ischemia and that this is cytokine driven [4, 74, 159]. Canine models of graft
endothelialisation have demonstrated that endothelial cells, originating from the blood
stream, contribute towards healing of the inner wall of Dacron grafts made impervious
to transmural capillary ingrowths [160, 161]. It has also been shown, in animal models
of carotid artery injury, that autologous EPCs can be harvested from blood and
transplanted into denuded vessels, resulting in preservation of vascular integrity [162,
163], EPCs arc therefore considered an important part of the natural repair mechanism,
helping to maintain vessel wall integrity and blood supply following organ ischaemia.
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EPCs have been identified and characterised using a number of different methodologies,
and these reflect the difficulty in precisely defining this diverse group of cells [4, 6, 7,
18, 164], They may express CD34, vascular endothelial growth factor receptor-2
(VEGFR-2), VE-cadherin, a junctional molecule, and AC 133, a receptor of unknown
function which is lost from EPCs as they mature [18]. VE-cadhcrin (CD 144) is thought
to be a specific marker of endothelial cells and a marker of more mature EPCs [165-
167]. EPCs are also defined functionally by their high proliferative capacity and ability
to form colonies in-vitro [7, 12, 19].
In spite of our understanding that ischemic insults and blood vessel damage are major
stimuli to EPC mobilisation, and the deposition at the site of tissue injury of mature,
functional endothelial cells [33, 74], there is uncertainty over where this maturation
event takes place or how dynamic a process it is. Knowledge of this process is hampered
by the lack of a simple universally agreed marker for EPCs. The objective of this study
was to investigate the dynamics of EPC mobilisation, using elective abdominal aortic
aneurysm repair in patients as a model of tissue ischemia and blood vessel damage. This
patient group undergo a relatively severe ischaemic event, in a controlled situation,
making them a very suitable model. In pre-operative and serial post-operative blood
samples we quantitated EPCs by a variety of techniques. Cell culture assays of
endothelial progenitors were used in combination with measurement of CD34, VEGFR-
2, CD 133, VE-cadhcrin and von Willebrand factor (vWF) expression by flow cytometry,




15 consecutive patients, who were undergoing elective abdominal aortic aneurysm
repair, were recruited. There were 11 males and 4 females. Their ages ranged from 54 to
85 years (median 72 years). Each patient underwent a laparotomy followed by insertion
of a Dacron graft (Scientific Medi-tech, NJ, USA) at the level of the infra-renal aorta.
5ml of blood was taken into EDTA coated tubes pre-operatively and at the following
times post-operatively: 24 hours, 48 hours and 5 days. A limit of a 5-day follow up was
chosen because patients were discharged on the following day. Furthermore, because the
operations were performed at a regional centre, patients had necessarily travelled long
distances, making it difficult to obtain blood samples after discharge. There were two
control groups used because the study was performed in two different centres. Group A
was the control group for the PCR studies, and group B was the control group for flow
cytometry and colony assay studies. Single samples for control group A were obtained
from patients attending an orthopaedic pre-operative clinic, who were found to have
normal routine full blood counts and serum biochemistry (6 males and 6 females,
median 71 years). Single samples for control group B were obtained from healthy
volunteers in the laboratory (8 males and 7 females, median 51 years). The study was
approved by the local ethics committee, and all patients gave written informed consent.
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Full blood counts
Full blood counts and differential counts, including monocyte counts, were obtained
from each patient, and at each time point, by collecting 2.7ml of EDTA anticoagulated
blood and processing the samples through a Sysmex analyser.
RNA extraction and real-time PCR
Protocols were followed as described in sections 2.1 to 2.3. I ml of whole blood was
subject to total leukocyte RNA extraction using Qiagen's "RNeasy mini-kit". RNA
concentration and purity were estimated by UV absorbance at 260 and 280 nm. The
260:280 nm ratios were all greater than 1.8 indicating that little protein contamination
was present. One microgram of total RNA was transcribed into cDNA in each reverse
transcription reaction with 200 units of M-MLV reverse transcriptase for 60 minutes at
37°C in 20pl reactions containing lpl (0.5pg/pl) of random hexamer primers, with
0.625pl (40units/pl) of RNase inhibitor, 5pl of dNTP mix (containing dATP, dCTP,
dGTP and dTTP, each at a concentration of lOnM in water) and 5pl of 5X RT reaction
buffer (containing 50mM Tris-HCL-pH 8.3 @ 25°C, 75mM KCL, 3mM MgCF and
lOmM DTT).
Real-time PCR was carried out using the AB1 Prism ®7900HT system (Applied
Biosystems, Warrington, Cheshire, UK) to determine the relative quantity (RQ) of
mRNA for selected genes. RQ can be defined as a comparison of a target signal in
different samples to a reference sample and normalised to an endogenous control [168],
166
PCR primers and probes for amplification of cDNA derived from CD34, VEGFR2, VE-
cadherin and vWF transcripts were obtained from Applied Biosystems (Foster City, CA,
USA). Each assay contained forward and reverse PCR primers (final concentration of
900nM each) and one TaqMan MGB probe (6-FAM dye-labelled, to a final
concentration of 250nM). All primer-probe sets had been quality control checked and
validated. The ribosomal 18s gene was used as the internal control. 4pi of the reverse
transcription reaction was analysed in each PCR reaction. The PCR reactions were run
in triplicate in 20pl assays, each containing cDNA, 1 pi of primer/probe, lOpl of
universal PCR master mix and distilled water. The cycling program was as follows: (a)
initial activation for 10 minutes at 95°C; (b) 50 amplification cycles with a 15 second
denaturing step at 95°C, and a 1 minute combined annealing and extension step at 60°C.
Analysis was performed using ABI 7900HT SDS software (version 2.1), in order to
obtain the relative quantities (RQ) ofmRNA compared to a calibrator.
Flow cytometry
The protocol in section 2.5 was used. Whole blood cells were phenotyped by flow
cytometry using FACS-Calibur flow cytometer (Becton-Dickinson, Oxford, UK). Cells
were directly stained and analysed for phenotypic expression of surface proteins with
monoclonal antibodies (MAbs) conjugated to phycoerythrin (PE), fluorescein
isothiocynate (FITC), Peridin Chlorophylla protein (PERCP) or Allophycocyanin
(APC). The MAbs included anti-CD34-FITC, PerCP-conjugated anti-human CD45, anti-
VEGFR2-PE, anti—cadherin-PE, and anti-CD 133-APC. Appropriate negative controls
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(Isotype and/or no antibody) were used to establish positive stain boundaries. lOOul of
the sample was stained with the appropriate antibodies for 30 minutes in the dark; the
erythrocytes were lysed with lysing solution for 15 minutes in the dark. Afterwards the
samples were centrifuged and washed with PBS at 200g and finally the cells were fixed
with Cell Fix solution. 50.000 events were counted and measured using the Becton
Dickinson FACSCalibur System. Percentage positivity for a particular marker was
obtained based on the total number of events. An absolute number was obtained using
the total white cell count. The mean fluorescent intensity (MFI) was obtained and
analysed for each marker for the total number of events and for the monocyte gate only.
Endothelial progenitor cell (EPC) colony assay
The protocol in section 2.6 was followed. The EPC colony assay was performed
according to the method specified by the kit manufacturer (Stem cell Technologies) after
the method of Hill et al [12], 3ml of venous blood was used to isolate endothelial
progenitor cells. The peripheral blood mononuclear cell fraction was isolated by Ficoll
density-gradient ceritrifugation. Recovered cells were then resuspended in Endocult.
5xl06 mononuclear cells in 2ml of Endocult were plated in a fibronectin-coated 6-wcll
plate and incubated for two days at 37C, 5% C02 with 95% humidity. After two days
the non-adherent cells were transferred into fibronectin-coatcd 24-well plates at
approximately lxlO6 cells/well for three days more at 37C, 5% C02 with 95% humidity.
2 days culture resulted in the emergence of characteristic endothelial progenitor
colonies. At day 5 of the assay the colonies per well were counted and the number of
EPCs per 106 cells plated in the fibronectin 24-well plate calculated. The colonies are
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defined following Stem Cell Technologies technical manual as a central core of "round"
cells with elongated "sprouting" cells at the periphery and are classified as early
outgrowth colony forming unit - endothelial cell or CFU-EPC.
5.3 Results
Comparison between patients and control subjects prior to aortic
aneurysm repair
Prior to surgery, there was no significant difference between the patient group and
control group A in the relative quantity of mRNA for CD34, VEGFR-2, VE-cadherin
and vWF (table 5.1). Furthermore, there were no significant differences between the
patient group and control group B in the number of EPCs by the colony assay and flow
cytometric measurements ofCD34, CD 133, VEGFR-2 and VE-cadherin (table 5,2).
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Table 5.1. Comparison between median RQ values in the control group and pre-
treatment patient group. The control group was cohort matched for age and gender with
the patient group. There were no statistically significant differences found between the
two groups in the RQ values for CD34 mRNA (p=0.237), VEGFR2 (p=0.6454), VE-
cadherin (p=0.863) and vWF (p=0.999).
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Table 5.2. Comparison of median colony numbers and median percentage positivity of
EPCs in controls versus prc-treatment patient group. The control group was not cohort
matched with the patient group. The control group had a higher median number of cell
colonies (0.23x104±0.06xl04) compared with the patient group (0.017xl04±0.03xl04).
This difference was statistically significant (p=0.005). There were no statistically
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significant differences between the groups in the median percentage of cells expressing
CD34 (p=0.7), CD 133 (p=0.93), VEGFR2 (p=0.18) and VE-cadhcrin (p=0.08).
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Leukocyte and EPC quantitation following surgery
Total white cell count and monocyte count. CD 14 expression by PCR:
Patients demonstrated an increase in the mean total white cell count by 24 and 48 hours
compared to pre-operatively (figure 5.1a). This was followed by a reduction to pre¬
operative levels by day 5. There was also an increase in the mean monocyte count by 48
hours post-operatively, but this did not reach statistical significance (figure 5.1b).
Samples from 14 patients out of 15 patients were assessed for the RQ of CD 14 mRNA.
There was an increase in the mean RQ by 24 and 48 hours, followed by a reduction in
the mean RQ by day 5 post-operatively (figure 5.1c).
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Figure 5.1. Effect of aortic aneurysm repair on the total white cell count (WBC), the
monocyte count and the RQ of CD14 mRNA. (a). Mean (±SEM) WBC increases from a
baseline of 7.13x109/l (±0.55) to 8.71x10'Vl (±0.79) by 24 hours, to a peak of
10.23x109/1 (±0.49) by 48 hours. The WBC then decreases by day 5 to 7.67x109/l (±0.5)
(p=0.0001). (b). Mean (±SEM) monocyte count increases from a baseline of 0.51x109/l
(±0.07) to 0.68x109/l (±0.06) by 48 hours. The monocyte count is 0.64x109/l (±0.05) by
day 5. The change in monocyte count is not significant (p=0.1). (c). The mean (±SEM)
RQ of CD 14 mRNA mirrors the change in the mean WBC count. There is an increase
from a pre-operative value of 1.06 (±0.16) to 1.74 (±0.31) by 24 hours. It increases
further by 48 hours, before falling slightly to 1.48 (±0.22) by day 5 following the
operation (p=0.001).
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CD34 expression by PCR and flow cytometry:
Complete data was obtained on 9 out of 15 patients for the RQ of CD34 mRNA (figure
5.2a). There was a reduction in the median RQ by 24 hours post-operatively, with a
recovery to the median pre-operative level by 48 hours. In addition, there was a
reduction in the median number of CD34+ cells by 24 hours post-operatively, before a
recovery to the pre-operative level by 48 hours (figure 5.2b). There was no significant
change in the MFI of CD34 in the total cell population or in the monocyte population
over the postoperative period (figure 5.3a&b).
CD 133 expression by PCR and flow cytometry:
Complete data was obtained on 6 out of 15 patients for the RQ of CD 133 mRNA. There
was an increase in the median RQ by day 5 following the operation, but this change did
not reach statistical significance (figure 5.2c). Samples from 8 patients were assessed
for surface expression of CD 133. There was a reduction in the median number of
CD 133+ cells by 24 hours, before a return to baseline levels by day 5 post operatively
(figure 5.2d). There was no significant change in the MFI of CD 133 post-opcratively in
the total cell population or in the monocyte population (figure 5.3c&d).
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VEGFR-2 expression by PCR and flow cytometry:
Complete data was obtained on 4 out of 15 patients for the RQ of VEGFR-2 mRNA.
There was a reduction in the median RQ by 24 hours, but this change did not reach
statistical significance (figure 5.2e). Samples from 9 patients were assessed for surface
expression of VEGFR-2. There was an increase in the median number of VEGFR-2+
cells by 48 hours post-operatively, before a return to the pre-operative level by day 5
after the operation, but this change did not reach statistical significance (figure 5.2f).
There was a statistically significant increase in the MFI of VEGFR-2 by 48 hours post¬
operatively in the total cell population and in the monocyte population, before a return to
baseline levels by day 5 (figure 5.3e&f).
VE-cadherin expression by PCR and flow cytometry:
Complete data was obtained on 14 out of 15 patients for the RQ of VE-cadherin mRNA.
There was a significant increase in the median RQ by 24 and 48 hours following
surgery, with a return to the pre-operative level by day 5 post-operatively (figure 5.2g).
Samples from 8 patients were assessed for surface expression of VE-cadherin. There
was no statistically significant change in the median number of VE-cadherin+ cells over
the specified time period (figure 5.2h). The MFI of VE-cadherin increased significantly
by 24 and 48 hours after the operation, when the total events were analysed, and when
the monocyte gate was analysed (figure 5.3g&h).
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VWF expression by PCR:
Complete data was obtained on 14 out of 15 patients for the RQ of vWF mRNA. There
was a significant reduction in the median RQ by 24 hours, followed by a recovery by 48
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Figure 5.2. Effect of aortic aneurysm repair on markers of EPCs by PCR and flow
cytometry, (a). The median RQ of CD34 mRNA transiently decreases by 24 hours,
before recovering to baseline by 48 hours, but this does not reach statistical significance
(p=0.03). (b). There is a reduction in the median number of CD34+ cells by 24 hours,
with recovery by 48 hours, but this does not reach statistical significance (p=0.04) (c).
The median RQ of CD 133 increases by day 5 following the operation, but this does not
reach statistical significance (p=0.15). (d). The median number of CD 133+ cells
increases from 24 hours to day 5 after the operation, but this does not reach statistical
significance (p=0.05). (e). The median RQ of VEGFR-2 mRNA increases by 48 hours
after the operation, but this does not reach statistical significance (p=0.75). (f). There is
an increase in the median number of VEGFR-2+ cells by 48 hours, but this does not
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reach statistical significance (p=0.5). (g). The median RQ of VE-cadherin mRNA
increases by 24 hours from baseline, and further increases by 48 hours, and by day5.
There is then a reduction in the median RQ of VE-cadherin mRNA from 48 hours to day
5 following the operation (p<0.0001). (h). There is an increase in the median number of
VE-cadherin+ cells by 48 hours after the operation, but this does not reach statistical
significance (p=0.41). (i). The median RQ of vWF mRNA falls significantly by 24 hours
from baseline. It recovers by 48 hours, and increases significantly by day 5 after the
operation (p<0.0001). Note: RQ values for the mRNA species studied were adjusted to














Figure 5.3. Effect of aortic aneurysm repair on the mean fluorescent intensity (MFI),
by flow cytometry, of the markers of EPCs. (a). There is no significant change in the
MFI of CD34 over the postoperative period when all cells are analysed (p=0.15). (b).
There is no change in the MFI of CD34 in the monocyte gate (p=0.46). (c). There is no
significant change in the MFI of CD 133 post operatively when all cells are analysed
(p=0.15). (d). There is no change in the MFI of CD133 in the monocyte gate (p=0.37).
(e). By analysing all cells, the MFI ofVEGFR-2 increases significantly by 48 hours post
operatively, before reducing back by day 5 (p=0.001). (f). By analysing the monocyte
gate, the MFI of VEGFR-2 increases significantly by 48 hours post operatively, before
reducing back by day 5 (p=0.001). (g). By analysing all cells, the MFI of VE-cadherin
increases significantly by 24 hours post operatively, before reducing back by day 5
(p=0.01). (h). By analysing the monocyte gate, the MFI of VE-cadhcrin increases by 48
hours post operatively, before reducing back by day 5, but this does not reach statistical
significance (p=0.02).
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Dual CD34 and VEGFR-2 expression by flow cytometry:
Complete data was obtained on 8 out of 15 patients for assessment of surface expression
of CD34 and VEGFR-2. There was a transient reduction in the number of CD34+,
VEGFR-2+ cells by 24 hours after the operation when all cells were analysed (figure
5.4a). When the total cell population was analysed, there was found to be an increase in
the number of CD34-, VEGFR-2+ cells by 24 hours post operatively (figure 5.4b). This
increase was sustained over the course of the study. When the monocyte population was
analysed it was also found that the number of CD34-, VEGFR-2+ cells increased by 48
hours following the procedure, but this change did not reach statistical significance
(figure 5.4c). There was a change in the number of CD133+, VEGFR-2+ cells post
operatively in the total cell population, with a doubling by day 5 (figure 5.4d).
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Figure 5.4. Effect of aortic aneurysm repair on EPCs, using dual staining ofmarkers by
flow cytometry, (a). When gated on all cells, the number of CD34+, VEGFR-2+ cells
falls by 24 hours post operatively, before recovering to baseline by 48 hours, but this
does not reach statistical significance (p=0.02). (b). When gated on all cells, the number
ofCD34-, VEGFR-2+ cells increases by 48 hours post operatively, before reducing back
by day 5, but this does not reach statistical significance (p=0.03). (c). When gated on
monocytes only, the number ofCD34-, VEGFR-2+ cells does not vary significantly over
the post operative period (p=0.08). (d). There is an increase in the number of CD133+,
VEGFR-2+ cells by day 5 post operatively, when all cells are analysed, but this does not
reach statistical significance (p=0.03).
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EPC colony assay:
Samples from 10 patients were assessed in the colony assay. There was a transient
reduction in the mean number of EPC colonies by 24 hours after the operation, but the
median change in values did not reach statistical significance over the measured time
period (figure 5.5).
Number of EPC-CFUs
Figure 5.5. The median number of EPCs in culture is reduced by 24 hours after the
operation, but this does not reach statistical significance (p=0.41).
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5.4 Discussion
Endothelial isation of vascular grafts is important in order to provide a non-thrombogenic
surface. Circulating EPCs are thought to play an important part in the vascular repair
process in adults. Therefore, endogenous mobilisation of EPCs after aneurysm repair in
humans is likely to play an important role in preventing potential graft induced thrombo¬
embolic events. The aim of this study was to investigate mobilisation of these cells,
using patients undergoing elective abdominal aortic aneurysm repair with Dacron grafts
as a model of vascular repair. Using three different techniques to investigate EPCs, we
demonstrated that circulating EPC numbers did not differ significantly in patients pre-
operatively compared to control subjects (tables 5.1&2). However, the circulating level
of these progenitor cells was altered following elective abdominal aortic aneurysm
repair.
The observation that there was no statistically significant difference in the level of
circulating EPCs in pre-operative samples compared with control samples is perhaps
surprising, knowing that reduced levels of circulating EPCs have been shown to be an
independent risk factor for the progression of atherosclerotic disease [169, 170]. The
lack of a difference in our study is likely to be due to a number of reasons. The patient
and control groups were not age and sex matched. Both variables are known to affect
EPC numbers, with older people having fewer circulating EPCs [56, 58, 171], Despite
our results showing a reduction in the number of EPC colonies in the patient group, the
median age of this group was significantly higher than that of control group B, and this
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difference is likely to have had an influence on the number of CFU-ECs counted in each
group (table 5.1). In addition, we investigated a different patient group at a time when
their vascular disease was clinically apparent. This is in contrast to the previous studies
investigating cardiovascular outcome events in healthy patients at risk of coronary artery
disease [169, 170],
The increase in the mean total white cell and monocyte counts observed following aortic
aneurysm repair suggests that the bone marrow is being stimulated to produce cells,
probably as part of an acute phase response (figure 5.1 a&b). The data presented in
figures 5.2, 5.3 and 5.4 suggests that EPCs are being mobilised as part of this response.
EPC mobilisation has been demonstrated previously in this patient group, reported by
Eizawa et al. [172], In this latter study, CD34 expression was noted to have doubled by
day 7 following the operation, which is in contrast to our findings (figure 5.2b). One
possible reason for this is that our study did not include this time point and, therefore,
the subsequent increase may have been missed.
Cytokine mobilised EPCs are thought to comprise less that 0.1% of the total circulating
mononuclear cell pool [18]. Therefore, even mobilised EPCs are few in number,
resulting in low levels of detectable mRNA, and consequently difficulty in amplification
of EPC mRNA as the PCR system reaches its limits of detection. This may explain why
there were incomplete data sets for the RQs of the EPC mRNA species studied. This is
particularly relevant to CD 133 and VEGFR-2, where complete data sets were only
achieved in 6 and 4 patients respectively. In contrast, only one patient failed to provide a
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complete data set for CD 14 mRNA, where CD 14 is expressed on a wider population of
cells and is known to be a marker of mature monocytes. Despite this, however, the
increase seen in the RQs of VE-cadherin mRNA, and in the number of cells expressing
surface CD 133, suggests that EPCs arc being mobilised as part of the overall bone
marrow response to tissue injury (figures 5.2d&g). In order to investigate phenotypic
expression on EPCs further we looked at the mean fluorescent intensity of the markers
studied, both in the total cell population and in the monocyte population only (figure
5.3). The reason that the monocyte population was studied is that there is emerging
evidence that monocytes are a major source of EPCs [24, 150, 173], The MFIs of
VEGFR-2 and Cadherin-cadherin were found to increase following the operation, both
in the total cell population and in the monocyte population, adding further evidence in
favour of EPC mobilisation following aortic aneurysm repair (figures 5.3e, f, g, h). We
also looked at cells by flow cytometry that were CD34-, VEGFR-2+ and CD34+,
VEGFR-2+ (figure 5.4). It was found that the number of CD34-, VEGFR-2+ cells
increased following the operation, when the total cell population was analysed (figure
5.4b). In contrast, the number of CD34+, VEGFR-2+ cells decreased transiently after
the procedure (figure 5.4a). Unfortunately, wc did not perform dual staining using
CD 14 and VEGFR-2, which is thought to be the specific subset of monocytes
responsible for cndothclial-like functional capacity [25], However, taken together this
suggests that EPCs are being mobilised from a CD34- pool of cells, which may be
monocytic in origin. The observation that there is a significant correlation between the
monocyte count and the number ofVEGFR-2 + cells in the patient group would seem to
agree with this (table 5.3).
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If CD34 is a marker of EPCs, it is difficult to reconcile the reduction seen in the RQ of
CD34 mRNA and the surface expression of CD34+, VEGFR-2+ cells with mobilisation
of EPCs, where one would expect to see an increase (figures 5.2a&b, figure 5.4a). One
reason for this could be that circulating EPCs are being sequestered in the immediate
post-operative period to the site of vascular injury, followed by a return to baseline
levels as further cells are mobilised and released from the bone marrow (or, just
possibly, as the sequestered cells are released back into the circulation). This would also
explain the transient trend in reduction seen in the number of EPC colonies (figure 5.5).
It is important to note, however, that CD34 is not a marker that is specific for EPCs, but
is also expressed by haematopoietic stem cells and by mature endothelial cells. This was
a limiting factor in the study by Eizawa et al, where CD34 alone was used as a marker of
EPCs [172], It could, therefore, be that there is sequestration of CD34+ cells and that
these cells are not EPCs but mature endothelial cells. This would explain the transient
reduction in the RQ of vWF mRNA observed in the immediate post-operative period
(figure 5.2i). In addition, it would explain why there is a statistically significant
correlation between the RQs of vWF and CD34 mRNA species (table 5.3).
As previously discussed, it has been discovered that the monocyte population in blood is
the main source of EPCs, rather than CD34+ progenitors as previously thought. An
interesting observation of the flow cytometry data was that in the patient group
approximately 90% of monocytes were positive for VE-cadherin (figure 5.6). In
addition, there were significant correlations found between the monocyte counts and
VE-cadherin levels (by PCR and flow cytometry), and between CD 14 and VE-cadherin
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mRNA RQs, but not between CD 14 and CD34 mRNA RQs (figure 5.7, table 5.3). This
suggests that Cadherin-cadherin is not specific to endothelial cells as previously thought,
but can also be expressed on monocytes. Furthermore, it could further demonstrate the
monocytic origin of EPCs.
In summary, we have demonstrated that a major vascular insult, such as aortic aneurysm
repair, results in the mobilisation of EPCs. Furthermore, these EPCs are likely to be
derived from the monocyte pool. Previous work has focussed on the time to mobilisation
of EPCs following a particular stimulus, or in-vitro maturation of EPCs. Our data gives a
more dynamic picture of how EPCs respond to a major vascular insult. It also highlights
the difficulty in measuring these cells using different techniques. This is presumably due
to a combination of small patient numbers, sensitivity of the techniques used to measure
this small population of cells, and the lack of consensus on an appropriate definition of
an EPC. Further work will involve recruiting more patients to the study in order to
extend our preliminary data, and to investigate whether some of the trends observed can
be better characterised. For example, the changes seen in the numbers of EPCs in the
colony assay, and the change in the RQ of VEGFR-2 over the period of the study.
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Correlation R2 value P value
Monocyte count us CD 14 0.1329 0.0057
mRNA RQ
Monocyte count vs VE- 0.0848 0.0295
cadherin mRNA RQ
Monocyte count vs number 0.214 0.0035
of VE-cadherin+ cells
Monocyte count vs number 0.2656 0.0007
of VEGFR-2+ cells
CD 14 mRNA RQ vs VE- 0.3579 <0.0001
cadherin mRNA RQ
CD 14 mRNA RQ vs CD34 4x10~6 0.9892
mRNA RQ
VWF mRNA RQ vs CD34 0.1835 0.003
mRNA RQ
Table 5.3. Correlation studies.
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Figure 5.6. The leukocyte fraction was isolated from a healthy blood donor buffy coat.
Cells were gated on all leukocytes (CD45+). (a). Side-scatter versus CD14. (b). Side-
scatter versus VE-cadherin. (c). CD 14 versus VE-cadherin. Most of the CD14+
monocytes are VE-cadherin positive.
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RQs of CD14mRNA
Figure 5.7. Graph showing a statistically significant correlation between CD14 mRNA
RQs and VE-cadherin mRNA RQs (pO.OOOl).
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6. ENDOTHELIAL PROGENITOR CELLS AND TYPE 1 DIABETES
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6.1 Introduction
People who have type l diabetes experience deficient wound healing secondary to a
lower capacity to form collateral vessels in areas of tissue ischaemia [ 174], Until
recently the reasons for this were not known, but with the identification of bone marrow-
derived endothelial progenitor cells (EPCs), it is now thought that the quantitative and
qualitative changes seen in this cell group in people both with type 1 and type 2 diabetes
are critical to the process of impaired neovascularisation [3, 80, 141, 175], EPCs have
been characterised by a number of methods. The most widely used are measurement of
the phenotypic expression of early (CD34, VEGFR2 and VE-cadherin) and late (VE-
cadherin and vWF) EPC markers, by the ability of EPCs to form mature endothelial cells
in culture, and demonstration of EPC incorporation into new vessels in animal models of
hind limb ischaemia [176], The aim of this study was to investigate the effect of type 1
diabetes on EPCs, using real-time PCR as a novel method of assessment, in addition to
the established methods of flow cytometry and cell culture.
6.2 Methods
EDTA anticoagulated blood samples (5mls) were collected from 45 people with type 1
diabetes attending the diabetes outpatient clinics at the Royal Infirmary of Edinburgh
and from 34 non-diabetic subjects (control group A). Approval was obtained from the
local medical research ethics committee (Lothian), and written informed consent was
obtained from each participant. Glycosylated haemoglobin (as HbAlc) was assayed
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using high-performance liquid chromatography adjusted to the Diabetes Control and
Complications Trial; the local non-diabetic range was 5.0-6.5%. Total leukocyte RNA
(lpg) was extracted from 1ml of blood using an extraction kit (Qiagen, Valencia, CA,
USA) according to the protocol in section 2.1, and transcribed into complementary
DNA using random hexamers (Promega, Madison, WI, USA), as described in section
2.2. Real-time reverse transcription polymerase chain reaction (RT-PCR) was performed
on an ABI PRISM 7900 Sequence Detector (Applied Biosystcms, Warrington, England)
using gene expression kits, containing primers and TaqMan probes for amplification of
CD34, VEGFR-2, VE-cadhcrin and vWF mRNA species (Applied Biosystems, Foster
City, CA, USA) (section 2.3). Ribosomal 18s was used as the endogenous control. The
relative quantity of each mRNA species was calculated as previously described [177].
In a parallel study, performed at a different laboratory, lOOql of the EDTA sample from
each of 21 of the patients with type 1 diabetes and from 15 different non-diabetic control
subjects (control group B) was directly stained and analysed for the phenotypic
expression of CD34, VEGFR2 and VE-cadherin using anti-CD34-FITC (Becton
Dickinson, Oxford, UK), anti-VEGFR2-PE (R&D systems), and anti-VE-cadhcrin-PE
labelled monoclonal antibodies (see section 2.5). Appropriate negative controls (isotype
and/or no antibody) were used to establish positive stain boundaries, and 50.000 events
were counted and measured by flow cytometry using a FACS-Calibur flow cytometer
(Becton-Dickinson, Oxford, UK). The percentage of cells positive for a particular
marker was determined from the events counted.
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In addition, 2ml of blood from 11 of the people with type 1 diabetes and from the 15
non-diabetic subjects (above) was subjected to centrifugation over a Ficoll gradient to
separate out the mononuclear cell fraction (see section 2.4). The pelleted cells were
resuspended in Endocult (composed from Endocult basal medium plus a 1/5 dilution of
Endocult supplements) (Stem Cell Technologies, UK) and cultured on fibronectin using
the same technique described by Hill et al [12]. At day 5 of the assay the EPC colony
forming units (EPC-CFU) per well were counted and the number of EPC-CFUs per cells
plated was calculated.
6.3 Results
No significant differences were found in the median RQ values of CD34, VEGFR2 and
vWF mRNA species between patients with type 1 diabetes and control group A (figure
6.1a-c, table 6.1). However, the patient group had a significantly lower median RQ of
VE-cadherin mRNA compared with the control group (figure 6.1 d). Furthermore, no
differences were found in the RQ values in patients with or without microvascular
disease or in patients with poorly controlled diabetes (table 6.1). A significant positive
correlation was found between vWF mRNA RQs and duration of diabetes (figure 6.2).
However, no correlations were found between the RQs of the mRNA species of interest
and HbAic levels (data not shown).
The patient group had a significantly lower median percentage of cells positive for
CD34 compared to control group B (figure 6.3). However, there were no differences
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found between the two groups for the other markers or for the percentage of cells
expressing both CD34 and VEGFR2 (table 6.2).
The median number of EPCs detected in control group B was significantly higher than












Number 37 - 45 - -
Mean Age 40.9 - 37.4 - 0.24
































































Table 6.1. Comparison between the diabetic group and non-diabetic group A of the
markers of EPCs detected by real-time PCR. Results are expressed as medians with
interquartile ranges. The unpaired t-test was used to compare mean ages of patient and
control group. MVD: microvascular disease. HbAlc: Haemoglobin Ale.
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Non-diabetic Interquartile People Interquartile P
controls (B) ranges with type
1 diabetes
ranges value










Median number 0.23 0.16-0.335 0.032 0-0.059 0.004
of EPCs (per 104
cells)
Median %CD34+ 0.06 0.05-0.09 0.02 0.02-0.05 0.003
cells
Median 1.89 0.885-3.06 4 1.21-32.33 0.14
%VEGFR2+
cells
Median %VE- 10.55 6.865-13.11 12.6 8.38-16.98 0.26
cadherin+ cells
Median % 24.39 5.73-37.345 15.08 0.222-43.5 0.35
CD34+VEGFR2+
cells
Table 6.2. Comparison between the diabetic group and non-diabetic group B of the
number of EPCs detected by flow cytometry and cell culture. Results are expressed as
medians with interquartile ranges. The unpaired t-test was used to compare mean ages of
patients and control group.
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CD34 mRNA RQ controls v diabetics
VEGFR2 mRNA RQ controls v diabetics
200000
210
vWF mRNA RQ controls v diabetics
diabetic
VE-cadherin mRNA RQ controls v diabetics
Patients
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Figure 6.1. The relative quantities of CD34 mRNA (a), VEGFR-2 mRNA (b), vWF
mRNA (c) and VE-cadherin mRNA (d) in the group with diabetes compared to control
group A. The median RQ of VE-cadherin mRNA was significantly reduced in the group
with diabetes compared to non-diabetic group A (2.24 versus 2.9, p<0.05, figure d)
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Duration of Diabetes
Figure 6.2. A positive correlation was observed between relative vWF mRNA level
and duration of type 1 diabetes. This correlation was not related to age (see text).
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% of CD34+ cells
Controls Patients
Figure 6.3. The percentage of cells expressing CD34 was significantly lower in the
diabetic group compared to non-diabetic group B (0.02% versus 0.06%, p<0.0005).
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Number of EPC-CFUs controls v diabetics
Controls Patients
Figure 6.4. The number of EPCs able to form endothelial colonies was significantly




The present study has shown that the group of people with type 1 diabetes had lower
amounts of VE-cadherin mRNA, a reduced percentage of CD34+ cells, and lower
numbers of EPC-CFUs in comparison with non-diabetic groups. VE-cadherin is an
adhesion molecule involved in angiogenesis and is specific to vascular endothelium
[ 178], Moreover, it is thought to be a marker ofmature EPCs [165], Reduction in the RQ
of VE-cadherin mRNA may reflect a lower number of EPCs in the diabetic group.
It has been demonstrated previously that the number of CD34+ cells extracted from
people with type 1 diabetes did not differ significantly from the number of CD34+ cells
extracted from non-diabetic control subjects [179]. Our findings contrast with this
observation. The discrepancy may, in part, be a consequence of a lack of effective
matching between diabetic and non-diabetic groups in the present study. In addition,
Schatteman et al used a different technique for quantification of CD34+ cells and quoted
absolute numbers instead of percentages [179]. Elowever, with data showing that CD34+
cclls accelerate vascularisation and healing in diabetic mouse skin wounds, the lower
percentage of CD34+ cells observed in the present group of diabetic patients may have
functional relevance to the number of EPCs capable of participating in
neovascularisation [180], This observation is strengthened by the present data which has
demonstrated fewer EPC-CFUs in culture compared to non-diabetic controls, which is
consistent with previous results [80, 179].
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Although a significant difference in vWF mRNA RQ was not demonstrable between the
diabetic and non-diabetic groups, a direct correlation between vWF mRNA RQ and
duration of diabetes was observed in the patient group (figure 6.2). This was not
apparent when vWF mRNA RQ and age in the non-diabetic subjects were compared
(r=0.30, p=0.07), implying that age itself was not the factor affecting vWF mRNA
levels. This is perhaps unsurprising as vWF is known to be a surrogate marker of
endothelial damage, and can predict the development of microvascular disease in
patients with diabetes [181, 182],
The major limitations of the present study were the lack of reproducibility of results
using markers of EPCs other than VE-cadhcrin and CD34 (tables 6.1&6.2), and the lack
of correlation between the different methods of analysis of the same marker. For
example, although a significant reduction occurred in the percentage of CD34+ cells in
the diabetic group, this was not reflected in the PCR data for CD34. One possible
explanation for this is that two different non-diabetic groups were used. It highlights,
however, the difficulty in measuring EPCs, which comprise a very small subset of the
circulating cell pool.
In summary, using a combination of three different techniques, the present study
suggests that circulating EPC numbers are lower than normal in people with type 1
diabetes. This may have important functional consequences in relation to their ability to
form collateral vessels as part of the vascular repair mechanism.
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7. ENDOTHELIAL PROGENITOR CELLS AND CHRONIC RENAL FAILURE
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7.1 Introduction
Patients with renal disease are known to have high morbidity and mortality rates from
cardiovascular disorders secondary to atherosclerosis, such as myocardial infarction and
stroke [183]. There are a number of potential reasons for this, but the process of
impaired vascular repair secondary to reduced numbers and/or impaired function of
EPCs as a cause has become a focus for further research. It has recently been
demonstrated that the number of EPCs in peripheral blood is significantly reduced in
patients with advanced renal failure when compared to age- and sex- matched controls
[82]. This has also been found to be the case in patients on maintenance haemodialysis
[81, 184], Moreover, it has been observed that uraemic serum can exert an inhibitory
effect on the differentiation capacity of EPCs in vitro, and on their capacity to migrate
and form tube-like (vascular) structures [82], One contributory factor to EPC deficiency
in patients with renal disease could be the lack of erythropoietin (Epo) [185], EPO is an
18-kDa protein consisting of a 166-amino-acid polypeptide chain linked by two
disulphide bonds. It undergoes post-translational glycosylation, which is essential for its
biological activity. It is encoded on a gene on the long arm of chromosome 7 and, in
adult life; this is expressed by the peritubular fibroblast-like interstitial cells of the
kidney. Epo circulates to the bone marrow and binds to Epo receptors (EpoRs) on
eiythroid precursors [186]. Mature endothelial cells have also been shown to express
EpoRs [187], Furthermore, Epo has been shown to induce a proangiogenic response in
cultivated mature endothelial cells, as evidenced by stimulation of endothelial cell
proliferation, migration, endothelin-1 release, and increase in cytosolic-free calcium
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concentration [188-191], With this background in mind, this study has been designed to
assess the effect of Epo on EPCs, by measuring changes in the RQ values of EPC
mRNA in patients with chronic renal failure who are commenced on recombinant
human Epo for the treatment of renal anaemia [192],
7.2 Methods
Five patients with stable CRF, who were felt to be candidates for EPO, were identified.
There were three males and two females, with a mean age of 65 years and a mean serum
creatinine of 327pmol/l. None of the patients had suffered form a recent acute coronary
syndrome or systemic inflammatory condition. 5ml of EDTA anticoagulated blood was
collected from each patient before they were commenced on EPO (Ncorecormon®, with
dose ranges from 4000 to 8000units/week), and then at serial time points up to 8 weeks
after commencement of therapy.
Total leukocyte RNA was extracted from 2.5ml of each sample using a standard
extraction kit (Qiagen) (section 2.1). The amount of RNA was determined by optical
densitometry. The RNA was then reverse transcribed using reverse transcriptase
(Promega), and the complementary DNA used in a real-time PCR system (section 2.2).
Primer-probe sets for CD34, VEGFR-2 and von-Willebrand factor (vWF) were
purchased through Applied Biosystems "assays-on-demand" (Warrington, UK), and the
96 well plates run on an ABI 7900HT thermal cycler. The endogenous control used was
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ribosomal 18s. Data generated was used to calculate the RQ of each mRNA species at
each time point (sections 2.3 & 3.3).
The remainder of each sample was spun down to separate off the plasma fraction, which
was then used in a quantitative sandwich enzyme immunoassay system (R&D Systems)




Patientl Patient2 Patient3 Patient4 Patient5 Median
Value
Pre Epo 1.00 1.09 0.63 0.73 0.71 0.73
Weekl 1.40 0.67 1.63 1.40
Week2 1.11 1.08 - 1.09
Week3 0.68 - 1.05 0.86
Week4 0.45 1.93 0.81 0.81
Week5 0.51 1.51 0.59 0.59
Week6 0.33 2.44 1.75 1.75
Week7 1.81 2.45 1.19 0.74 0.71 1.19
Week8 1.69 12.49 1.13 1.69
Table 7.1. Compared to baseline there is an increase in the median CD34 mRNA level
of 62% (p=0.06) by week 7 after commencement of Epo. This is depicted graphically in
Figures 7.1 a&b. The peak value was observed at week 8 after starting Epo.
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Patientl Patient2 Patient3 Patient4 Patient5 Median
Value
Pre Epo 1.00 - 0.38 - - 0.69
Weekl 0.49 0.34 1.11 0.49
Week2 0.33 - - 0.33
Week3 - - 0.59 0.59
Week4 - 0.46 0.67 0.57
Week5 0.66 0.18 - 0.42
Week6 - 0.90 0.19 0.54
Week7 0.65 0.40 - - - 0.53
Week8 0.73 - 0.22 0.48
Table 7.2. Compared to baseline there appears to be very little change in the level of
CD 133 mRNA. Too few data points were present for statistical analysis. This is
represented graphically in Figure 7.2.
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Figure 7.2





Patientl Patient2 Patient3 Patient4 Patient5 Median
Value
Pre Epo 1.00 1.79 1.16 - 2.70 1.47
Weekl 1.94 2.69 2.19 2.19
Week2 2.10 1.39 - 1.75
Week3 5.89 - 2.51 4.20
Week4 3.55 2.24 1.30 2.24
Week5 16.39 1.68 1.11 1.68
Week6 9.11 1.59 5.36 5.36
Week7 2.79 4.67 5.05 - 3.55 4.11
Week8 1.27 - 1.42 1.35
Table 7.3. Compared to baseline there is an increase in the median level of VEGFR-2
mRNA of 179% by week 7 after commencement of Epo (p<0.05). The peak increase
appears to be by week 6 after starting Epo. This is depicted graphically in Figures
7.3a&b.
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Patientl Patient2 Patient3 Patient4 Patient5 Median
Value
Pre Epo 0.21 0.35 0.48 0.38 0.32 0.35
Weekl 0.13 0.55 0.50 0.50
Week2 0.32 0.48 - 0.40
Week3 - - 0.95 0.95
Week4 0.28 0.68 0.37 0.37
Week5 0.37 0.49 0.37 0.37
Week6 0.15 0.60 0.91 0.60
Week7 0.19 1.28 1.11 0.24 0.30 0.30
Week8 0.82 0.82 1.00 0.82
Table 7.4. Compared to baseline there is no change in the median value of VE-cadherin
mRNA by week 7 after commencement of Epo (figure 7.4a). However, as depicted in
figure 7.4b, there appears to be an upward trend in the level of VE-cadherin expression
in patients 1, 2 and 3 by week 8 after starting Epo.
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Patientl Patient2 Patient3 Patient4 Patient5 Median
Value
Pre Epo 0.15 0.18 0.39 0.32 0.65 0.32
Weekl 0.10 0.25 0.96 0.25
Week2 0.24 0.18 - 0.21
Week3 0.29 - 0.46 0.38
Week4 0.25 0.18 0.68 0.25
Week5 0.65 0.25 0.48 0.48
Week6 0.24 0.21 1.13 0.24
Week7 0.20 0.30 0.38 0.30 0.43 0.30
Week8 0.37 0.23 1 0.37
Table 7.5. Compared to baseline there is no change in the median value of vWF mRNA
by week 7 after commencement of Epo. This is depicted graphically in Figures 7.5a&b.
230
Changes in vWF mRNA




Patientl Patient2 Patient3 Patient4 Patient5 Median
Value
Pre Epo 474 211 236 238 77 236
Weekl 255 171 325 255
Week2 82 191 356 191
Week3 189 312 0 250
Week4 230 26 345 230
Week5 264 432 272 272
Week6 359 265 302 302
Week7 329 289 298 226 271 289
Week8 160 259 244 244
Table 7.6. Compared to baseline there was no significant change in the median value of
VEGF by week 7 after the commencement of Epo. This is depicted graphically in
Figures 7.6a&b.
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The effect of human recombinant Epo on the transcription of CD34, CD 133, VEGFR-2
and VE-cadhcrin (all markers of EPCs) and vWF (as a marker of mature endothelial
cells) has been investigated in a group ofpatients with chronic renal failure, using a PCR
based technique for quantitation of mRNA for these proteins. In addition, the effect of
Epo on the amount of plasma VEGF protein in the same patients has been investigated,
using an ELISA based technique.
The number of patients recruited to this study was very small. In addition, we did not
examine EPCs by flow cytometry or in cell culture in this study. As a result it was
difficult to draw any firm conclusions from the results that could be based on solid
statistical analysis. However, there appeared to be an increase in the median level of
CD34 mRNA, although this change did not quite reach statistical significance (figure
7.1). In addition, there was a statistically significant increase in the median level of
VEGFR-2 by week 7 after the commencement of Epo (figure 7.3a). Furthermore, there
was an increase in the median level of VE-cadherin by week 8 of EPO treatment, but
this did not reach statistical significance (figure 7.4). These changes in suggest that EPC
levels may be increased following commencement of Epo. The lack of a significant
change in the median amount of vWF mRNA would suggest that mature endothelial
cells arc not affected in the same way (figure 7.5). This would certainly fit with the
current understanding regarding Epo and EPC stimulation, where Epo has been shown to
be a powerful stimulatory agent for EPC proliferation and functional activity [90, 193,
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194], A marked and persistent stimulation of EPC recruitment in vitro and in vivo was
demonstrable even at sub therapeutic doses of Epo when used to treat renal anaemia. In
our study therapeutic doses of Neorecormon® were used. Our data did not show any
change in the amount of plasma VEGF following commencement of Epo (figure 7.6). It
has been known now for some time that VEGF is an important cytokine in the
stimulation of EPCs form the bone marrow [31]. Our results suggest that EPCs may be
mobilised by a VEGF independent route. This would fit with other groups who have
demonstrated that Epo can directly stimulate EPCs via the Akt tyrosine kinase signalling
pathway [90, 193, 195], We could not demonstrate a change in the amount of CD 133
mRNA (figure 7.2). This was due in part to the low subject numbers studied, but also to
the fact that there was failure of amplification at may of the time points in each series.
The reason for this is uncertain, but it may just reflect the very low level of PCR product
from a cell that is found in low numbers in the periphery, resulting in a fall below the
limit of detection in the system used. Another observation that is difficult to explain is
the variation observed in the RQ of a particular marker in a patient over the period of the
study. For example the variation in the amount of vWF mRNA in patient 3 (figure
7.5b), or the transient increase in the level of VEGFR-2 mRNA at week 5 following
commencement of Epo in patient 1 (figure 7.3b). This may be due to natural variation in
the level of these mRNA species, but may also be due to a transient vascular insult in the
patient. Von-Willebrand factor, for example, has been shown to be a surrogate marker of
vascular injury, and VEGFR-2 levels have been shown to increase following an episode
of renal ischaemia-reperfusion [181, 182, 196, 197].
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Stimulation of EPCs by Epo could represent a new therapeutic strategy in cardiovascular
medicine in order to prevent the sequelae of atherosclerotic vascular disease. This
approach may be particularly useful in patients with renal failure, a population at high
risk of cardiovascular complications. In this respect, administration of Epo might be




Identification and enumeration of EPCs present in the adult remains difficult and non-
standardised. The reasons for this are numerous, and may partly explain the discrepancy
in results and lack of correlation between different assays supposedly measuring the
same marker in this thesis. Primarily, it is unclear whether EPCs are truly bone marrow
derived from primitive cells (a putative haemangioblast) or from differentiated cells (like
monocytes) that acquire an endothelial cell-like phenotype [22, 23, 198], Similarly, it
remains to be clearly established to what degree vessel wall derived cells can contribute
to the circulating pool of endothelial progenitors. For example, it has recently been
shown that the vessel wall may also contain highly proliferative EPCs capable of
forming colonies with re-plating potential (HPP-ECs) [199, 200], Furthermore, the
pathway of HSC maturation is not fully defined and it is possible that expression of
CD34 and CD 133 may be continuously up and down-regulated. It has been suggested
that stem cells are continuously altering their phenotype and these alternations are
reversible [201], Thus, many described cell phenotypes could represent a single cell in
different functional states. Finally, it has been suggested that rather than a hierarchical
transition from stem cells to progenitor cells, fluctuation continues to exist in which
stem cells adjust their phenotype depending on the cell kinetic state activated by their
genetic program or micro environmental stimuli [202], The data presented in this thesis
also suggests that no single marker is truly specific for EPCs. Rather, a number of
markers are likely to be needed. This is particularly important when utilising these
marker combinations to best identify CEC and EPCs prior to clinical application of such
cells.
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No single assay appears to reliably measure EPCs, suggesting that either there are
differences in the sensitivity of detection of a particular assay and/or that different cell
populations are being detected. A limitation in using singleplex real-time PCR in the
studies is that the assumption has to be made that each amplicon is being amplified from
the same cell or cell population. This may not be the case, however. One potential way
to confirm this would be to perform in-situ RT-PCR to detect gene expression directly
within a cell population. With the knowledge that the putative population of EPCs is
likely to be less than 1% of the leucocyte pool, a limitation of the flow cytometry assay
used in the studies is that 50,000 events may not have been a sufficient number to
capture this population. Other studies have used nearer 1 million events in such "rare
event analysis". Finally, with recent studies showing that that progenitor cells adherent
to fibronectin after 2 days in culture may contain the definitive EPC population, a
limitation of the "Hill" culture assay used in the studies is that it will detect monocyte -
derived EPCs only [203].
In general, it is very difficult to interpret and compare results between studies because
each group uses their particular EPC definition based on their experimental and/or
clinical outcomes. CD34 and CD133 arc both haematopoietic markers, but these
populations are only partially overlapping. Similarly, VEGFR2 and VE-cadhcrin
antigens are present in subpopulations of each fraction and only a low percentage of
these cells co-express together. Therefore, there is only a small chance that all these
different EPC definitions refer to the same cell population. The combination of the
expression of these three markers could reflect a hierarchy of EPC differentiation or
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cells in different kinetic states, which would explain why different groups achieved
different results. It may also explain why using the in vitro functional EPC assay (EPC-
CFU), which could be thought of as a more global measure of the EPC numbers,
appeared to provide more interpretablc results in this thesis than the real-time PCR or
flow cytometry data, which may have measured different cells at different stages of
maturity. Despite this, however, all three techniques used appeared to demonstrate a
change in EPCs, whether it was due to exogenous vascular insult, or secondary to
endogenous vasculopathy or administration of a recombinant protein. A more accurate
definition for EPCs will be required first before further assay comparisons can be
performed.
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